Transforming Microtubules into Microshuttles for Advanced Immunoassay Applications. by Campbell, Jenna Marie
Transforming Microtubules into Microshuttles  
for Advanced Immunoassay Applications 
 
 
by 
 
 
Jenna Marie Campbell 
 
 
 
 
 
 
 
 
A dissertation submitted in partial fulfillment 
of the requirements for the degree of 
Doctor of Philosophy 
(Mechanical Engineering) 
in the University of Michigan 
2014 
 
 
 
 
 
 
 
 
 
Doctoral Committee: 
 
 Professor Edgar Meyhöfer, Chair 
 Assistant Professor Barry Grant 
 Assistant Professor Ajit P. Joglekar 
 Professor Katsuo Kurabayashi 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
© Jenna Campbell 2014 
All Rights Reserved 
	  
	  
	  
	  
	  
	  
	  
	  
ii 
	  
	  
	  
	  
	  
	  
	  
For Lisa Orr and Vivek Tomer— 
For pushing me forward every time I wanted to take a step back. 
Your love, support, and guidance have been invaluable. 
 
 
 
 
 
 
 
 
 
 
iii 
ACKNOWLEDGEMENTS 
 
 This dissertation is the culmination of many years of work, which would 
not have been possible without the guidance of my advisor, Edgar Meyhöfer. He 
challenged me, taught me how to ask questions, and how to “do science.” 
Always having an open door, your support and expertise has been invaluable 
academically, professionally, and personally.  
 I would also like to acknowledge Katsuo Kurabayashi for your expertise 
and support. Our meetings gave me a broader perspective on our projects, which 
played a large role in shaping my academic and professional goals. Committee 
members Ajit Joglekar and Barry Grant have always been generous with their 
time, and I am thankful for the advice and expertise they have given throughout 
my graduate career. My co-workers Charles Jiang and Neha Kaul played a 
critical role in this work. Thank you for bringing laughter along with great 
insight into my work. 
 I would like to acknowledge Professor James Gole for encouraging me to 
continue my education, which brought me to the University of Michigan. I 
would not have discovered my love of science and research if it were not for 
your passion to inspire undergraduates and educate young scientists.  
 Finally, my friends and family who have supported me have been critical 
to my accomplishments over the last five years. Vivek Tomer has given me 
guidance, advice, and support that was so helpful in overcoming every hurdle I 
encountered at Michigan. Megan Roberts and Marilyn Gatewood are two 
brilliant female engineers that I am fortunate to have as role models and friends. 
My greatest thanks goes to Lisa, Casey, Claire, and Hannah whose patience, love, 
and support have carried me through my whole life and will take me through 
many more years.  
iv 
 
TABLE OF CONTENTS 	  
DEDICATION .................................................................................................................. ii 
ACKNOWLEDGEMENTS ............................................................................................. iii 
LIST OF FIGURES .......................................................................................................... vii 
LIST OF TABLES ........................................................................................................... viii 
LIST OF ABBREVIATIONS ........................................................................................... ix 
CHAPTER 1: MOTIVATION ..........................................................................................1 
CHAPTER 2: BACKGROUND ........................................................................................3 
2.1 Microtubule-Kinesin Systems: From In Vivo Motility to Lab on a Chip 3 
Microtubules as Nanoshuttles .................................................................5 
Highly Engineered Cargos ......................................................................7 
Kinesin Motor Control .............................................................................8 
Mechanical Control of Microtubules ....................................................10 
Electrophoretic and Magnetic Control of Microtubules ....................12 
2.2 Proteomic Biosensors ....................................................................................13 
2.3 Kinesin-Driven Immunoassay Platform ....................................................17 
Microtubule Concentrator .....................................................................17 
Motivation and Potential for Immunoassay Applications ................19 
Hurdles in Combining Kinesin and Microtubules in Proteomic 
Sensors ......................................................................................................20 
CHAPTER 3: ANTIBODY-FUNCTIONALIZED NANOSHUTTLES DRIVEN BY 
BIOMOLECULAR MOTORS FOR SENSITIVE IMMUNOASSAY 
APPLICATIONS .............................................................................................................24 
3.1 Introduction ...................................................................................................25 
3.2 Approach ..........................................................................................................2
v 
3.3 Results .........................................................................................................................28 
Specificity and Binding Capacity of Antibody-Functionalized 
Microshuttles ...........................................................................................28 
Motility Properties of Antibody-Functionalized Microshuttles .......36 
Limitations for Sandwich Assay Construct .........................................37 
3.4 Conclusions ....................................................................................................41 
3.3 Experimental Section ....................................................................................42 
Microtubule Preparation ........................................................................42 
Kinesin Purification ................................................................................43 
Microtubule Antibody Conjugation .....................................................43 
Ellman’s Reagent Assays .......................................................................44 
Binding Capacity Assays .......................................................................45 
Motility Assays ........................................................................................46 
 
CHAPTER 4: KINESIN AND MICROTUBULE COMPATABILITY IN HUMAN 
URINE, SALIVA, AND BLOOD PLASMA .................................................................47 
4.1 Introduction ...................................................................................................47 
4.2 Biotinylated Microtubules and Their Ability to Bind Streptavidin           
Cargos in Human Urine, Saliva, and Blood Plasma ......................................49 
4.3 Microtubules and Their Motility Properties in Human Urine, Saliva, 
and Blood Plasma ................................................................................................55 
4.4 Motility Characteristics Required for Steering Microtubules in Kinesin-
Driven Technologies ...........................................................................................57 
4.5 Motility Properties of Kinesin and Microtubules in Human Blood 
Plasma ...................................................................................................................64 
Unfiltered Blood Plasma ........................................................................65 
Filtered (10 kDa) Blood Plasma .............................................................69 
4.6 Conclusions ....................................................................................................71 
4.7 Experimental Section ....................................................................................72 
Human Sample Preparation: Blood Plasma ........................................72 
Human Sample Preparation: Saliva .....................................................73 
Human Sample Preparation: Urine ......................................................73
vi 
 
Microtubule Preparation ........................................................................74 
Binding Capacity Assays .......................................................................75 
Quality of Motility ..................................................................................76 
 
CHAPTER 5: CONCLUSIONS AND FUTURE WORK ............................................77 
5.1 Conclusions ....................................................................................................77 
5.2 Future Work: Fluorescent Detection Via Labeled Detection  
Antibodies ............................................................................................................79 
Modifying Assay Geometry to Support the Transport of Large 
Cargos .......................................................................................................80 
Modifying MT-Antibody Conjugation Procedure to Support the 
Transport of Large Cargos .....................................................................81 
Transport Fewer, Larger Cargos to Sustain Motility .........................84 
5.3 Future Work: Kinesin-Driven Immunassay Platforms in Blood  
Plasma ...................................................................................................................84 
Separate Sample Collection from Gliding Assays ..............................85 
Engineer Technologies Accommodating for Motility in Blood 
Plasma .......................................................................................................86 
5.4 Future Outlook for Kinesin-Driven Technologies ...................................88 
 
WORKS CITED ................................................................................................................90 
 
 
 
 
 
 
 vii 
LIST OF FIGURES 
 
Figure 2.1 Geometry of gliding assay…...……………………..………….…..…….  5 
Figure 2.2 Microtubule being guided mechanically………...…………………….  11 
Figure 2.3 ELISA assays……………………...……………………………...……….  14 
Figure 2.4 Microtubule concentrator device……………....……………………….  18 
Figure 3.1 Conjugation protocol…………………………………………………….  27 
Figure 3.2 Schematic representation of binding assay………...………………….  29 
Figure 3.3 Antigen specific binding and binding capacity……………………….  31 
Figure 3.4 Image processing for binding capacity measurements…….………...  33 
Figure 3.5 Functionalized microtubules support motility…...……..…………….  37 
Figure 3.6 Effect of antibody sandwich cargo on kinesin-microtubule gliding 
assay…………………………………………………………………………………...  40 
Figure 4.1 Microtubules binding TMR-streptavidin cargos in body fluids…….  53 
Figure 4.2 Gliding assay velocities in body fluids………………………...……....  56 
Figure 4.3 High quality motility and the effects of aggregation…...…………….  59 
Figure 4.4 Floating ends are detrimental to guiding microtubules……..……….  62 
Figure 4.5 Gliding assay motility in blood plasma…...………………..………….  66 
Figure 4.6 Gliding assay motility in 10 kDa filtered blood plasma…..………….  70 
 
 
 
 
 
 
 
 
 viii 
 
LIST OF TABLES 
 
Table 1 Competitive immunoassay formats and assay conditions……..……….  16 
Table 2 Profiles of body fluids commonly used for diagnostic tests…………….  21 
 
 
 ix 
 
LIST OF ABBREVIATIONS 
 
Ab Antibody 
AMPPNP Adenylyl-imidodiphosphate 
ATP Adenosine triphosphate 
BSA Bovine serum albumin 
Bt Biotin 
CSF Cerebral spinal fluid 
Cy5 Cyanine-5 
DNA Deoxyribonucleic acid 
DTT Dithiothrietol 
GTP Guanosine triphosphate 
IL-6 Interleukin-6 
kDa Kilodalton 
LOC Lab on a chip 
MT Microtubule 
PBS Phosphate-buffered saline 
PCR Polymerase chain reaction 
PIPES Piperazine-N,N'-bis(2-ethanesulfonic acid) 
POC Point of care 
SDS-PAGE Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
SMCC Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-
carboxylate 
SPR Surface plasmon resonance  
STV Streptavidin 
TMR Tetramethylrhodamine 
 
1 
CHAPTER 1 
MOTIVATION 
 
Advances in clinical diagnostics and health care critically depend on new 
tools to efficiently and reliably analyze complex patterns of bio- and disease 
markers. There is significant evidence that proteomic approaches to analyze 
arrays of biomarkers are very effective in early disease detection including 
cancers, and low budget, point-of-care proteomic sample analysis would be 
beneficial in improving global health care.[1-7] Currently, enzyme-linked 
immunosorbent assays (ELISA) are the most common protein analysis methods, 
but their sensitivity is usually limited by some relative threshold concentration 
(1-10pM) that, in some cases, is too high to detect early stages of disease 
progression.[8, 9] Since no protein amplification techniques exist, analogous to 
polymerase chain reactions for DNA, surpassing this threshold concentration (1-
10pM) is difficult.[10],[11-13] The ultimate objective of my dissertation is to progress 
an innovative ELISA-based nanotechnology that allows for rapid capture and 
specific transport of biomolecules using a single, small (nanofluidic) sample 
volume and limited manual labor without the need of an external power source.  
The nanotechnology is an engineered protein system that takes advantage 
of the kinesin and microtubule system that nature has taken the time to develop. 
Only for the last several decades have researchers been exploring the potential 
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the cytoskeletal transport systems have in vitro and in lab on chip technologies. 
Here, I bridge the gap in knowledge that exists in taking the kinesin-microtubule 
system out of biological cells and into advanced lab on chip ELISA-based 
diagnostic devices for point of care applications. With progress in the fields of 
nano- and microfluidics and bioengineering being key to progressing medical, 
point if care diagnostic devices, the development of nanoscopic ELISA platforms 
that are capable of capturing and detecting ultralow concentrations of proteins is 
essential in further advancing these medical technologies.   
Leveraging cytoskeletal transport systems for microscopic transport 
systems that are highly regulated in biological cells brings a significant 
advantage when compared with entirely man-made systems. In such protein-
based systems, biologists and engineers can work in parallel to advance our 
understanding of the regulation mechanisms of the system and, therefore, 
contribute to advancing autonomous regulation mechanisms in lab on chip 
devices. Biological discoveries relating to the specificity of the cytoskeletal 
transport system can be incorporated into such a device eventually turning it into 
a “smart” device guided by nature’s protein regulation mechanisms.[14]  
Implementing a protein analysis requiring a small sample volume at very 
low cost will reduce trauma to more sensitive patients and allow for future 
biomolecular motor-driven technologies to serve as a low budget, bed-side 
health diagnosis tool having global health care applications. As such 
technologies progress, they will facilitate a paradigm shift, particularly in 
detection of the early onset of diseases and continuous health monitoring
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CHAPTER 2 
BACKGROUND 
 
In this chapter I will begin by discussing the previous work that has been done 
over the last two decades in taking the kinesin and microtubule system out of a 
cell and into in vitro systems. I will discuss the advances scientists and engineers 
have made in modifying the protein system to transport specific cargos and 
control and regulate its motility. The previous work will be framed to highlight 
the future potential the kinesin-microtubule system has to be integrated into lab 
on a chip technologies and, specifically, point of care medical diagnostic devices. 
Then, I will look at the current demands for medical diagnostic devices and the 
approaches others have taken to engineer technologies that satisfy those 
demands.  Culminating these two topics, I will conclude with a more specific 
example as to how the kinesin-microtubule system can be integrated into micro- 
or nanofluidic devices and be engineered to satisfy the demands for point of care, 
lab on chip proteomic detectors for sensitive diagnostic tests.  
 
2.1 Microtubule-Kinesin Systems: From In Vivo Motility to 
Lab on a Chip 
 
During the last decade many advances have been made in revealing the 
complexities of the nano- and microscale systems existing in biological cells. 
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Progress has been made in getting these systems to function in in vitro 
environments where they can be studied as independent systems. Due to their 
robustness in vitro and nanoscopic properties, several of these protein systems 
often serve as an inspiration for nano and micro technologies.[14-19] One system of 
particular interest is the active transport system present in eukaryotic cells. Here, 
organized networks of microtubules and actin filaments in the cytoskeleton of a 
cell provide tracks for a variety of biomolecular motors, such as kinesins, to 
move along and generate mechanical forces. These motor molecules power 
cellular mechanical processes including cell contraction and movement, mitosis, 
and intracellular transport by directly converting chemical energy (hydrolysis of 
ATP) into mechanical work.[20, 21] Adenosine triphosphate (ATP) powers the 
stepping motion of kinesin. The chemical energy extracted from the hydrolysis of 
ATP in this kinesin ATPase is converted to mechanical work as the motor 
molecule steps along the microtubule protofilament. The motor protein kinesin is 
responsible for intracellular transport and has many properties that have 
attracted considerable interest in these molecules as energy transducers and 
transport systems for nanotechnology applications.[15, 22] Kinesins are nanoscopic, 
move processively along MTs for micrometer-long distances, support high speed 
(several µm/s), use little energy, and the microtubules (MTs) kinesin travel along 
are stable, robust tracks that can be readily engineered into artificial lab on a chip 
devices. [14, 15, 18, 23-31] 
While studying kinesin-MT systems in in vitro environments, a typical 
assay will take place in a microfluidic chamber. Kinesin motor molecules 
nonspecifically bind to the surface of the chamber. A motility buffer containing 
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Figure 2.1 Geometry of a gliding assay. Plus-end directed motors step along the 
MT surface towards the plus end to propel the MT along the glass surface. 	  
ATP and MTs is then flown into the chamber. The kinesin motor domain 
exposed to the ATP-containing motility buffer binds to MTs free in solution. 
Kinesin motors step along the MTs with an inherent directionality. As illustrated 
in Figure 2.1, when all of the kinesin step in the same direction along the MT, the 
kinesin motor molecules push MT along the kinesin-coated surface of the 
microfluidic chamber. This is known as a gliding assay. MTs can glide along the 
surface uninterrupted for several millimeters at speeds >1 µm/sec without any 
external pumps or power sources. These qualities and the scale of the system are 
ideal for active transport in microfluidic systems.  
 
Microtubules as Nanoshuttles 
Due to the appealing active transport mechanism the MT-kinesin system 
provides in vitro, there have been a number attempts to functionalize 
microtubules as it appears to be the simplest way to adapt this protein system 
into a useful active transport mechanism in microfluidic, lab on chip (LOC) 
systems.[24, 32] The first cargos carried utilized biotinylated tubulin and the strong 
biotin-streptavidin (Bt-STV) linkage.[33] Streptavidin is multivalent, so a Bt-STV-
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Bt sandwich is easy and inexpensive to create. These Bt-STV functionalized MTs 
have been utilized to transport and even manipulate biotinylated DNA using a 
Bt-STV-Bt linkage.[34-37] Biotinylated nanospheres, quantum dots and 
microspheres all served as cargoes on biotinylated MTs.[38-40] Once this MT-Bt-
STV-Bt-cargo linkage was optimized, the next logical step was to use this 
modified tubulin to attach biotinylated antibodies to microtubules to transport 
specific proteins.[41, 42] These conjugations brought about a lot of excitement as 
they introduced the kinesin-microtubule system into potential immunoassay 
platforms.  
The major disadvantage to the Bt-STV-Bt linkage is undesired crosslinking 
that is possible due to the multivalent properties of STV. The assay must be 
carefully done in many sequential steps to reduce the number of undesired MT-
MT, cargo-cargo, or MT-cargo-MT crosslinking events that result in clusters of 
undesired byproducts. Some researchers purposely crosslinked microtubules in a 
controlled manner using the Bt-STV-Bt linkage to create clusters of microtubules 
in different geometries such as linear nanowires or nanospools.[43, 44] However, 
the future applications for such geometries are still unclear. Later on, a variety of 
more specific conjugation techniques were developed to covalently link 
antibodies to microtubules using homo- or heterobifunctional crosslinkers.[45, 46] 
While these techniques are an improvement to the biotin-dependent alternatives, 
most still leave room for undesirable cross-linked products similar to the Bt-STV 
linkage.  
As these MT microshuttles evolved, the LOC kinesin-driven platforms 
also had to advance in hopes to effectively incorporate these systems into useful 
devices. Here, I will discuss the different ways researchers have manipulated this 
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transport system and engineered devices to accommodate the controllable 
properties of kinesin and microtubules. It remains largely unclear how biological 
cells control the chemo-mechanical activity of kinesin motors to achieve the 
complex and specific transport properties present in cellular function.[47-52] 
Theoretically, if the underlying control mechanisms that drive this highly 
regulated intracellular transport were completely understood, one could create 
and control a highly specific, infinitely multiplexed device that relies solely on 
proteins and protein modifications to deliver cargos. Since these control 
mechanisms are not fully understood, it is not clear how kinesin and 
microtubules can be harnessed to their fullest potential for specific 
multidirectional micro transport. Several attempts have been made to overcome 
this limitation by utilizing the inherent chemical and mechanical properties of 
the kinesin-microtubule system or engineering micro- or nanofabricated 
structures or “smart” polymers to have better control of this system, which are 
discussed further below. Significant strides in engineered biological systems 
must be made to further understand how fully take advantage of kinesin and 
microtubules in LOC technologies.  
 
Highly Engineered Cargos 
While significant work has been done to functionalize MTs, several 
groups have gone a step further in engineering cargos and tethers that collect, 
transport, and deliver cargos. Being able to control the transportation or delivery 
of micro or nanoscaled cargo is ideal in microreactors, concentrators, or targeted 
activation. All of the developed techniques incorporate engineered DNA 
primers. Complimentary DNA primers linked to the MT and the cargo enable 
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pick up, and a more preferential complementary primer is exposed on the 
delivery site with the purpose of pulling the cargo off of the microtubule. 
Brunner, et al. developed a microfabricated surface that enabled crossing MTs to 
pick up treated microspheres with DNA tethers.[53] The Vogel and Sutoh group 
went beyond by gathering, transporting, and delivering a specific analyte to a 
deposition region using complementary DNA mentioned previously.[54, 55] While 
successful, this requires a highly engineered cargo, which is not desirable for 
broad medical diagnostic purposes that typically depend on a huge library of 
antibodies for proteomic detection but may be reasonable for other micro scale 
applications.[56-60] 
 
Kinesin Motor Control 
While our knowledge of what naturally controls kinesin motors in 
biological cells is limited, many have taken the most basic understandings of 
kinesin motors and engineered systems that can turn motility on and off in 
gliding assays. Controlling the accessibility of ATP in solution can regulate 
motility. This concept has been utilized by developing stimuli-responsive 
polymers to cage ATP.[61] Rahim, et al. and Hess, et al. used ATP caged by a 
photoresponsive polymer that releases ATP into the microfluidic chamber after 
being exposed to an ultraviolet pulse.[62, 63] The Diez group used a thermo 
responsive polymer to create a similar reversible stop and go motility control in a 
gliding assay format. Instead of controlling the ATP in solution, this polymer 
could be activated to block kinesin motor domains and prevent MTs from 
binding and traveling along the kinesin surface. The polymer is nonspecifically 
adsorbed to the substrate alongside kinesin motors. When cooled to 27°C, the 
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polymer expands and physically blocks access to the motor domain, preventing 
MT-kinesin interactions. When heated to 35°C the polymer finds a more 
preferable conformation, tangled closer to the glass surface and exposes the 
kinesin heads to the MT containing motility buffer.[61] Recently, Diez also 
engineered the opposite configuration to create controlled motility where the 
polymer was bound to the MT instead of the kinesin surface.[64] The rate of 
kinesn’s ATPase activity increases at higher temperatures thus supporting a 
proportionately higher velocity. Unfortunately, the variation in kinesin activity is 
not significant enough to use as a robust signal, so using these dynamic thermo-
responsive polymers is advantageous at functional temperature ranges.[65-67] 
Taking control over the motor molecule, the Bachand group engineered a kinesin 
motor that contained a divalent metal binding site in the neck linker region. 
Exposing motors to a solution containing divalent metal ions inhibits kinesin, 
thus preventing motility. The inhibition can be reversed by introducing a 
number of chelating agents into the system.[68]  
Engineering the kinesin to exhibit desirable characteristics is a timely and 
expensive endeavor, but with the improvement of computational modeling, 
highly engineered motors may not be too far away.[69, 70] Since motors are the 
backbone to active, directed intracellular transport in vivo, looking at engineered 
and natural motor control mechanisms is ideal for making these nano-transport 
systems more complex and highly regulated in vitro. A lot of future potential lies 
in multiplexed and advanced cargo delivery by focusing on motor control.  
 
 
 
	  	   10 
Mechanical Control of Microtubules 
Many attempts to mechanically control the directionality of microtubule 
movement have been made by utilizing the physical interaction between 
oncoming microtubules and barriers with which they interact. This work was 
pioneered by the Meyhöfer and Kurabayashi group where Lin, et al. developed a 
model that illustrates that the MT bends and is guided in the direction that is 
most energetically favorable when coming in contact with a kinesin-free wall 
(See Figure 2.2).[71, 72] In gliding assays microtubules can bend at angles smaller 
than that suggested by their persistence length because tens or hundreds of 
kinesin motors are applying a force that outweighs the Brownian motion that 
cause bending.[73] In these gliding assays a majority of the microtubule is bound 
to kinesin, but the very tip remains free and controls the directionality of the 
gliding motion. Without interference from a mechanical blockade, the tip, free of 
kinesin, is limited to bending due to thermal energy. In this model and 
experimentally, the direction in which the MT bends when it hits a kinesin-free 
wall depends on how the very tip of the microtubule is directed.[74]  
This interaction is also dependent on the material properties of the wall.[75-
78] If a MT approaches a wall coated with functional kinesin molecules, there is 
some probability the MT will travel over the wall dissociate from the kinesin-
coated surface instead of being steered by the wall. Surfaces can be fabricated 
and treated to be unaccommodating to proteins binding which have been 
utilized to create physical barriers in microfluidic chambers. For example, an 
extremely hydrophobic surface will cause proteins to denature and become non-
functional. Lin and others have used this mechanical steering of MTs with some 
blockade to autonomously guide MTs to specific regions or in a certain  
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 Figure 2.2 Microtubule being guided mechanically. As microtubules come in 
contact with a wall (black line on right), the thermally diffusing leading minus end 
(left) is guided in the direction that is most energetically favorable. As a result, 
the MT follows this motion and is steered by the wall as it glides forward (right).  
 
direction.[77, 79-82] Specifically, the microfabrication process developed by Lin has 
become the typical standard for mechanically guiding MTs in micro- and 
nanofluidic systems.[79] CYTOP is deposited on a glass wafer and etched away 
using SF6 reactive ion etching, exposing the glass surface. Under specific 
fabrication parameters, kinesin motors bind and support motility on the exposed 
glass surface. The CYTOP can be coated with a Pluronic polymer and then 
possess material properties that cause kinesin to denature and prevent motility 
on the CYTOP walls. These walls then serve as mechanical barriers that guide 
MTs throughout the glass channels. 
Additional mechanical constraints can be placed on the system by 
interfering with the kinesin-MT binding. Many have studied the effects of 
coating MTs with nanoparticles, for example, and observed effects on motility.[83-
85] One group engineered a microfabricated device to sort microtubules by length. 
Microtubule length can be controlled by adjusting the polymerization 
parameters during tubulin growth or by shearing stabilized microtubules with a 
Hamilton syringe or pipette tip.[86] The Sato group created a biased gradient of 
microtubules of different lengths by fabricating microtrenches that allow only 
MTs of a length greater than the width of the trench to cross. Shorter 
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microtubules fell off the ledge and could not bridge the gap to continue transport 
to the other side of the trench.[87] Engineering a system that sorts or guides 
microtubules mechanically lessens the importance of using highly modified 
proteins for controlling the system and supports autonomous control that is 
promising for multiplexing.  
 
Electrophoretic and Magnetic Control of Microtubules 
Microtubules have an inherent negative charge on their surface.[88] This 
charged surface is thought to be important in motor-MT binding events.[69, 70] 
Many have utilized this negative charge by guiding, aligning or manipulating 
MTs using electrophoresis.[32, 88-90] Van den Heuvel, et al. implemented 
electrophoresis into a concentrator device to separate MTs at a Y-junction with 
two different fluorescent labels.[89] A charge was applied across a Y-junction to 
either attract or repel MTs to the appropriate channel. While successful, this 
approach requires constant surveillance of incoming filaments at a single Y-
junction, a large and expensive research microscope, and has low throughput. 
Microtubules have also been aligned and manipulated using dielectrophoresis, 
and, additionally, using a magnetic field after magnetic particles were attached 
to one end of the MT.[91, 92] While the previous work utilizing dielectro- and 
electrophoresis is binary (attraction or repulsion, alignment or randomization), 
this technique has potential in multiplexing kinesin-driven devices. Changing the 
surface charge of a microtubule or conjugating a material with different 
dielectrophoretic properties would allow researchers to tune and multiplex a 
device steered by an electric field. Although, a potential hurdle is that changing 
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the surface properties of the MTs may affect the kinesin interactions and impair 
motility. 
While there has been great development in manipulating and controlling 
this cytoskeletal system in vitro, the only successful attempts at autonomously 
multiplexing a device were done by sorting MTs by length. The advances that 
have been made in utilizing the kinesin-microtubule system in more applied 
LOC technologies looks promising. Like many LOC systems that incorporate 
biological systems, the desire to miniaturize medical devices, including 
diagnostic devices, and transform them into smaller point of care (POC) 
technologies that are easier to use and more reliable is desired. In the following 
section, I discuss recent advances in microfluidics and immunoassays and how 
they benefit future point of care diagnostics. Then, I will assess how the work 
done with the kinesin-microtubule system can merge with the demands of 
proteomic biosensors which motivates the foundation of my dissertation, 
developing a kinesin-driven ultrasensitive immunoassay platform. 
 
2.2 Proteomic Biosensors 
The current demand in the field of proteomic biosensors is to develop a 
more sensitive, less invasive, inexpensive, rapid diagnostic device.[93-95] The most 
commonly used proteomic detection mechanism is an enzyme-linked 
immunosorbent assay (ELISA) (See Figure 2.3). ELISA assays are typically 
performed on a plate containing several wells. In direct ELISA assays the base of 
each well is coated with a capturing antibody that specifically captures a protein 
of interest. The unbound sample is rinsed from the well and a detection antibody  
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 Figure 2.3 ELISA assays. Capturing antibodies (purple) specifically bind to 
protein antigen. A detection antibody that is fluorescently labeled is either 
complimentary and binds the protein of interest (pink) or secondary and binds 
the end of the detection antibody (blue).  
 
is flown in. The fluorescently tagged detection antibody is complementary to the 
antigen and binds to the analyte that was initially captured by the capturing 
antibody, forming an antibody sandwich. In an indirect ELISA assay protein is 
nonspecifically adsorbed to the base of the well along with the other proteins in 
the sample. The capturing antibody binds only the protein of interest, or antigen, 
in the well. The detection antibody in indirect ELISA is a secondary antibody that 
binds to the heavy chain of the capturing antibody. The signal from the label on 
the detection antibody is measured, and this signal corresponds to the amount of 
analyte in the initial sample. These assays have a typical detection limit of 1-100 
pM which is limited by either the sensitivity of the fluorescent measurement or 
the affinity of the analyte to the antibody.[96] While there has been a significant 
amount of effort to improve the affinity of antibodies to reach affinities on the 
order of a femtomolar, this is an extremely expensive and timely endeavor and is 
generally not used for improving the sensitivity of these assays for a wide variety 
of biomarkers.[97-106] Thus, to improve the sensitivity of proteomic biosensors and 
maintain an affordable cost for patients, other technologies have been developed 
to challenge the typical well-based ELISA approach. Common techniques 
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employed by technologies used today to surpass the standard ELISA limitations 
include the following:  
 
• Lower detection limits: Increase the signal to nose ratio for 
fluorescence or rely on other, more sensitive detection methods 
apart from fluorescence or amplify the analyte signal. 
• Faster assays: Allow antibody to diffuse within the sample instead 
of relying on the diffusion of analyte to an antibody-coated surface.  
• More accurate tests limiting error: Create an autonomous lab on a 
chip device that reduces human error. 
• Reduce costs and invasiveness of test: Downsize to nano- or 
microfluidic systems that require smaller sample and reagent 
volumes to lower costs. Smaller samples are less invasive to 
sensitive patients such as newborns. Less invasive tests permit 
more frequent testing or monitoring the progression of diseases or 
therapies.[107] 
 
Table 1 shows comparisons between typical ELISA well assays and competing 
approaches that currently exist on the market and their assay specifications. 
Notice the tradeoffs in each technology. Some improve the detection limit but 
lack ease of use or specificity while others improve ease of use and have 
comparable detection limits.  Trade offs exist for all of these technologies being 
developed. As seen in the table below, progress has been made in engineering 
and manipulating microfluidic immunoassay platforms to reach lower detection 
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limits, lower costs, reduce human induced error, and reduce assay time. While 
microfluidics had a role in accomplishing all of these tasks, existing methods to 
significantly reduce the detection limit that rely on bioengineering, such as the 
rolling circle amplification and engineered high affinity antibodies, are often too 
expensive and too highly engineered to translate into practical, broad, high 
throughput diagnostics. My dissertation work incorporates several of the 
concepts inspired by the above technologies along with the previously discussed 
potentials in incorporating the kinesin-MT system into LOC devices. 
 
2.3 Kinesin-Driven Immunoassay Platforms  
Microtubule Concentrator 
Engineers have explored the various ways to manipulate the kinesin-
microtubule system using their mechanical or electrostatic properties or altering 
biochemistries as discussed in Section 4.1. While these concepts have been 
fundamentally explored, it was not until the Meyhofer and Kurabayashi groups 
began integrating the kinesin-microtubule system into engineered microfluidic 
devices that the motor proteins looked promising for advanced, applied 
technologies. Taking what was known regarding mechanically steering 
microtubules, they designed a microtubule concentrator device powered by 
kinesin motor molecules that autonomously guided and trapped microtubules in 
a concentrator region.[72, 80] 
 The concentrator device illustrated in Figure 2.4 is constructed using the 
aforementioned fabrication process that selectively promotes kinesin 
functionality in etched glass regions while CYTOP walls guide microtubules into  
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Figure 2.4 Microtubule concentrator device. The device is engineered to 
autonomously guide MTs to a center concentrator region (top right). 
Perpendicular CYTOP walls (bottom right) guide the MT tips that come in contact 
with the wall. To adapt the device for POC LOC diagnostic device, antibody 
functionalized MTs would incubate with the sample (left) and be concentrated in 
the device for detection. Figure adapted from Lin, et al. Nanoletters 8(4), 2008. 
 
 
a concentrator region. Microtubules land in the kinesin-coated, glass petal-
shaped regions where they are transported by kinesin in a gliding assay. While 
the instantaneous directionality of the microtubules cannot be controlled, over 
time, the geometry of the curved CYTOP walls surrounding the petal regions 
guides the microtubules into the center of the device. As microtubules reach the 
center of the device, they enter into the concentrator region. The concentrator 
region is comprised of arrowhead, shaped glass surfaces that are covered with a 
parylene cover. The arrowhead regions, lined with CYTOP walls, cause the 
microtubules to serpentine within the concentrator region. If the microtubules 
disassociate from the glass (xy) surface, then the parylene cover prevents 
microtubules from escaping the concentrator region from the z direction. As a 
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result, millimeters of microtubules can enter into a microfluidic chamber and 
then be specifically concentrated into a 25 µm x 25 µm concentrator region in less 
than 30 minutes. 
  
Motivation and Potential for Immunoassay Applications 
 Reflecting on the previous discussion in Section 4.2 on engineering 
advanced immunoassay platforms, concentrating analyte, working with small 
(<µL) sample volumes, and creating a diagnostic platform that is not complicated 
for the end user are all of interest in the field of medical diagnostics. Diagnostic 
devices for point-of-care (POC) applications have additional criterion including 
the following: working with non-invasive samples, requiring no ancillary 
equipment, and being easy to use. Using antibody functionalized microtubules 
as nanoshuttles that can collect and transport specific analytes combined with 
Liu’s microtubule concentrator has great potential in advancing current 
immunoassay technologies.  
 Each concentrator requires only 0.13 nL of sample, concentrates 
millimeters of microtubules, and runs solely off of chemical energy (ATP). These 
traits coupled with antibody functionalized microtubules and an on-chip 
detection mechanism would make this system ideal for a potential POC 
diagnostic device. To transform this microtubule concentrator into an 
immunoassay platform, two critical gaps in knowledge must be addressed to 
realize its potential. First, the antigen binding capacity of the microtubules must 
be properly characterized using various biochemistry and protein 
characterization techniques to ensure that relevant detection capabilities can be 
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realized in the system. Second, all aspects of the system (kinesin, microtubules, 
motility, antibody-antigen binding, etc.) must not be compromised when 
immersed in medically relevant samples.  
 
Hurdles in Combining Kinesin and Microtubules in Proteomic Sensors  
Sustaining various protein functions in these relevant protein systems 
(kinesin, microtubules, antibody and antigen) in medically relevant biological 
samples is a hurdle that has yet to be addressed. Samples required for protein-
based diagnostics include, but are not limited to, blood, urine, saliva, 
cerebrospinal fluid (CSF), and tissue extracts.[93] Cytoskeleton components 
including kinesin and microtubules are not inherently found in biological fluids; 
their natural environments are inside eukaryotic cells. In the proposed kinesin-
driven immunoassay platform, motility and stability of the microtubule-kinesin 
construct must remain stable to concentrate antigen. Immersing kinesin and 
microtubules into protein-rich biological samples where they are not necessarily 
inherently compatible brings concern to their ability to remain motile and 
functioning because protein-protein interactions, whether they are specific or 
nonspecific, can be detrimental to in vitro assays. The complexity and diversity of 
such samples can be seen in Table 2. Due to the heterogeneity found in biological 
samples, it is unknown whether there are protein-protein interactions that will 
interfere with the kinesin-microtubule construct in vitro. Antibodies and their 
antigens, however, are found in abundance in blood samples. The antigenicity of 
antibodies and their antigens are found relatively unaffected when immersed in 
various biological fluids. They are manufactured, verified, and then 
commercially sold to clinicians to use in ELISA assays in various biological  
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Sample pH 
Protein 
Concentration 
(mg mL-1) 
Ionic 
Strength 
(mmol L-1) 
Commonly Used to Detect 
Blood Plasma 7.3-7.5 50-70 145 Proteins, cholesterol, glucose, small molecule drugs 
Urine 4.6-8.0 0.1-13.5 150-300 Hormones, small molecule drugs, blood cells 
Saliva 6.2-7.7 0.7-2.5 44-163 Local (oral) microbes and proteins, DNA 
Cerebrospinal 
Fluid 7.2-7.3 0.3-0.7 130-170 
Neurological disorders, 
infection, neurological damage 
Table 2 Profiles of body fluids commonly used for diagnostic tests[113-117] 
 
samples. So, the biggest concern in incorporating biological samples into the 
microtubule concentrator device is whether the kinesin-microtubule construct 
will be negatively affected in the protein-rich samples. A previous study by 
Korten et al observed the effect cell lysates; blood serum and plasma; and buffer 
solutions conducive to PCR and labeling techniques had on cytoskeletal 
transport systems.[118] The motivation for their work was to establish a kinesin-
based platform for personalized genomic diagnostic applications. In this Korten 
et al study the kinesin-MT system was found to be compatible with blood plasma 
and blood serum when blood derivatives made up 0.1% of the buffer solution; 
with cell lysates that contained 5000 cells µl-1; and a variety of buffer solutions 
and were not compatible in DNA hybridization conditions.  
The array of proteins signaling the presence, progression, or regression of 
diseases is unique to each individual disease. The protein landscape required of 
various diagnostics is diverse and varies in complexity (number of analytes 
required for proper diagnosis), sensitivity (detection or concentration limits 
required), and temporally (protein landscape may change at various stages of the 
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disease). And, the protein landscape of each disease is unique in each type of 
bodily fluid used for the diagnosis. Today, blood serum and plasma are the most 
common samples used in proteomic ELISA assays because of they tend to 
contain relatively high concentrations of proteins present, which is desirable as it 
makes the assay more robust. However, all of the other aforementioned 
biological samples have distinct benefits that are driving the development of new 
diagnostic test platforms. 
 Reflecting back on the four facets driving diagnostic technologies (lower 
detection limits, faster assays, more accurate tests limiting error, and reducing 
the costs and invasiveness of tests), protein concentrations affecting detection 
limits and the method of obtaining the biological sample affecting the physical 
invasiveness of the test are the two facets that are governed by the sample as 
opposed to the engineering of the diagnostic device. While blood contain high 
concentrations of proteins, it is invasive to collect the sample from the patient 
because it require breaking the patients skin, similar to CSF. Furthermore, the 
more invasive samples require skilled technicians, sterilized equipment, and can 
only be taken in limited amounts so as not to negatively affect the patient. The 
invasiveness of these protein-rich samples is a major limiting factor in many 
diagnostic tests in resource-limited environments. Relying on non-invasive 
samples such as saliva and urine is more desirable as they are less expensive, 
available in large volumes without affecting the patients’ well being, and 
eliminate the risk of infection or agitation to the patient. However, the trade off 
associated with these non-invasive samples is that common protein biomarkers 
are generally found in lower amounts if they are even present at all. As 
mentioned in the prior discussion on proteomic biosensors, advances in 
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engineering and scaling down diagnostic tests is lending the field to more 
robustly being able to detect lower concentrations of proteins for disease 
detection. These engineering advances are, therefore, encouraging the 
development of new diagnostic standards and arrays to be investigated and 
implemented into diagnostic devices using noninvasive samples that I will 
further explore in this dissertation.   
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CHAPTER 3 
ANTIBODY-FUNCTIONALIZED NANOSHUTTLES 
DRIVEN BY BIOMOLECULAR MOTORS FOR 
SENSITIVE IMMUNOASSAY APPLICATIONS 
 
In this chapter I discuss the progress I made in further advancing and 
characterizing antibody functionalized microtubules that can be used for 
sensitive immunoassay applications. I developed a covalent conjugation 
technique that uses a heterobifunctional crosslinker to specifically attach 
antibodies to microtubules resulting in antibody-functionalized nanoshuttles for 
innovative immunoassay platforms. This technique is effective for a variety of 
antibody types, is highly specific, binds high densities of antibody (>100 
antibodies µm-1 of microtubule), and does not sacrifice the active transport 
properties of microtubules and their kinesin motor counterparts. The conjugation 
design allows antibody-functionalized microtubules and antigen to diffuse freely 
in solution, which significantly reduces typical enzyme-linked immunosorbent 
assay (ELISA) times. The nanoshuttles can be concentrated to yield very high 
antibody to antigen ratios ideal for ultralow antigen detection or to remove 
undesired proteins or dyes from solution. Intrinsic motility characteristics of the 
complementary biomolecular kinesin motors can be incorporated into advanced 
actuation or concentration mechanisms in micro- or nanofluidic devices ideal for 
novel immunoassay platforms.  
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3.1 Introduction 
In clinical settings detecting low levels of protein via immunoassays that 
leverage high affinity antibodies is critical for early disease detection. In the past 
decade the miniaturization of immunoassay platforms and a variety of 
microfluidics-based lab on a chip (LOC) designs have been a major driving force 
in a steady progression towards lower detection limits, reduced assay times, and 
less invasive procedures.[119, 120] One strategy is to harness the MT-kinesin 
transport system as microshuttles for nano biotechnology applications, as 
justified in Chapter 2. This approach led several groups to functionalize 
microtubules with antibodies with the intent to transport specific target protein 
cargos in LOC systems.[24, 32, 33, 41, 42, 45, 46] While data from this work support this 
general concept, existing protocols broadly suffer from a range of limitations. 
First, functionalized MTs should ideally be able to freely diffuse within the 
sample without creating crosslinking byproducts such as MT and antibody 
aggregates. Freely diffusing MTs significantly reduce incubation times, reduce 
the complexity of handling procedures, prevent MT aggregates from forming 
that hinder in vitro motility, and reduce the unnecessary waste of expensive 
reagents. Crosslinking was most prevalent in conjugation techniques that relied 
on multivalent streptavidin-biotin linkages or homobifunctional crosslinkers. 
Second, conjugation methods should be applicable to a wide variety of 
commercially available antibodies including antibody fragments and 
recombinant antibodies. Third, the binding capacity, meaning the number of 
functional antibody molecules per length of MT, needs to be high to realize 
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assays capable of detecting femto- to nanomolar protein concentrations. To 
develop sensitive and robust immunoassays, it is therefore essential that this 
metric be quantified to evaluate the potential of functionalized MTs for 
immunoassay platforms. Additionally, antibody-functionalized microtubules 
must retain their motile properties with biomolecular motors.  
To achieve my goal of realizing antibody-functionalized microtubules 
with the full complement of properties desired for advanced immunoassay 
applications, I developed and quantitatively characterized a covalent conjugation 
technique that utilizes a heterobifunctional crosslinker to specifically conjugate 
antibodies to microtubules. This technique prevents undesired crosslinking 
byproducts, is effective for monoclonal, polyclonal, recombinant, and f(Ab)’2 
antibodies, is highly specific, binds high densities of antigen and does not 
sacrifice the motility properties of the MT-kinesin system.  
 
3.2 Approach 
The basic approach to our method is outlined in Figure 3.1. A free amine 
on the polymerized MT surface and a reduced sulfhydryl group on the antibody 
heavy chain are covalently linked via the heterobifunctional succinimidyl 4-(N-
maleimidomethyl)cyclohexane-1-carboxylate (SMCC) crosslinker (Pierce 22360). 
SMCC is 8.3 Å long and contains an amine-reactive succinimidyl (NHS) ester 
moiety on one end and a sulfhydryl-reactive maleimide moiety on the other. The 
sulfhydryl group on the antibody intended for modification is an attractive target 
because it neither sterically nor chemically interferes with the antigen-binding 
domain, which is ideal for a successful immunoassay platform.  
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Figure 3.1 Conjugation protocol.  Microtubules functionalized with the 
heterobifunctional SMCC crosslinker. Monoclonal, polyclonal, or f(Ab)’2 
antibodies were reduced, and the exposed disulfide bond on the antibody heavy 
chain was covalently bound to the SMCC-coated MT surface. 
 
The labeling procedure begins by activating MTs with an excess of SMCC 
crosslinker. The amine-reactive NHS ester reactions were continued for 30 
minutes at room temperature to allow sufficient crosslinker binding to the MTs. 
Detailed characterizations of SMCC-labeled MTs (MT-SMCC) via Ellman’s 
Assays also showed that the hydrolysis of the maleimide moiety of SMCC to 
maleamic acids was sufficiently slow (see Experimental Section) such that the 
reactivity for binding antibodies is preserved under these labeling conditions.[121] 
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After the MT-SMCC conjugation, excess SMCC was removed from solution to 
promote antibodies binding to MT-SMCC and avoid antibodies binding to 
crosslinker free in solution. To remove free SMCC from solution, MT-SMCC 
were spun in an ultracentrifuge (Beckman Airfuge) for 30 seconds at 30 psi 
through a 60% glycerol cushion containing 20 µM paclitaxel (LC Laboratories 
P9600) and resuspended in a sodium phosphate buffer with 20 µM paclitaxel. 
The disulfide bonds linking the antibody heavy chains were reduced in a 50 mM 
2-Mercaptoethylamine (2-MEA) solution for 90 minutes at 37° C to separate the 
two heavy chains. To prevent any further reduction of antibody, excess 2-MEA 
was removed through a buffer exchange column.[122, 123] This also avoids 
interference with maleimide-sulfhydryl binding. Reduced antibodies were 
immediately added to MT-SMCC at a 2-, 6-, or 10-fold molar excess with respect 
to the total tubulin concentration, and the solution incubated for 2.5 hours at 
room temperature to complete the conjugation. Then, free antibodies were 
removed by pelleting the antibody-functionalized MTs via centrifugation and 
resuspending them in 80 mM PIPES buffer containing 20 µM paclitaxel.  
 
3.3 Results 
Specificity and Binding Capacity of Antibody-Functionalized Microtubules 
To characterize the specificity and binding density of antigen on the 
functionalized MTs, I performed binding assays as illustrated in Figure 3.2 using 
microtubules functionalized with polyclonal anti-bovine serum albumin (anti-
BSA) (Molecular Probes, A11133), pepsin digested f(Ab)’2 anti-BSA, or 
monoclonal anti-human interleukin 6 (anti-IL-6) antibodies (Invitrogen,  
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 Figure 3.2 Schematic representation of binding assay. Antibody-functionalized 
microtubules are labeled with either fluorescently tagged labeling antibody (left) 
or a fluorescently tagged antigen (right) in binding assays. The kinesin-coated 
glass substrate also supports gliding motility when ATP is available in solution. 
 
CHC1263). The assays were carried out in simple microfluidic chambers 
constructed form microscope slides and coverglasses. First, I sequentially coated 
the chambers with buffer solutions containing casein and kinesin that adsorbed 
to the glass surfaces. This reduces nonspecific binding of free antigens or 
fluorophores to the glass surface during the assays. In addition, when MTs were 
introduced in the microfluidic chambers, they bound to kinesin motors 
(specifically the N-terminal motor domains) attached to the glass surface. 
Consequently, the microtubules were held nanometers from the glass surface for 
imaging. When ATP was present in the assay buffer, MTs were transported 
along the kinesin-coated surface in in vitro gliding assays. Tetramethylrhodamine 
(TMR)-labeled BSA served as the anti-BSA antigen while unlabeled IL-6 in 
combination with an anti-IL6 biotinylated detection antibody labeled with TMR 
streptavidin was used to detect anti-IL6 on the MT surface. To qualitatively 
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analyze how antibody-functionalized MTs capture their respective antigens, I 
polymerized fluorescently-labeled microtubules by incorporating a small fraction 
of Cy5-labeled tubulin, functionalized the microtubules with antibodies using 
our SMCC crosslinking protocol and then used fluorescence microscopy to 
separately image microtubules and complementary as well as non-
complementary antigens. As illustrated in Figure 3.3a, antigen molecules bound 
to MTs functionalized with complementary antibodies but not to MTs with non-
complementary antibodies or unlabeled microtubules. For example, as shown in 
the third column of Figure 3.3a, TMR-BSA bound only to anti-BSA 
functionalized MTs while untreated and anti-IL-6 functionalized MTs showed 
negligible rhodamine fluorescence signals in the presence of even very high 
concentrations of TMR-BSA (100 nM).  Similarly, the binding behavior of IL-6 
(second column) shows interactions with complementary anti-IL-6 
functionalized MTs while untreated MTs and anti-BSA functionalized MTs did 
not bind IL-6. I also note fluorescent specks in the images not associated with 
MTs, particularly in the complementary antigen TMR images. Based on a 
number of control experiments, I believe that these specks represent labeled, 
functionalized MT fragments that invariably result from the handling procedures 
associated with pelleting and resuspending MTs.  Note however, that these 
specks do not represent background nor nonspecific labeling associated with the 
functionalized MTs. All of the IL-6 images were taken using TIRF microscopy at 
higher magnification (note the longer scale bars). IL-6 assays had lower signal to 
noise ratios and, therefore, inherently highlight the residual fluorophore on the 
glass surface, which is an artifact of incomplete protein blocking. Taken together, 
these observations suggest that the binding of antigen to functionalized MTs is  
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Figure 3.3 Antigen specific binding and binding capacity. a.) Cy5 microtubules 
were either treated with polyclonal anti-BSA IgG (top row), monoclonal anti-IL6 
(middle row), or not treated (bottom row) and incubated with 100 nM TMR-BSA 
(right column) or 100 nM IL-6 and TMR labeled detection antibody (middle 
column). Antigen binding is specific to treated, antibody-functionalized 
microtubules. Labeling IL-6 with a fluorescently-tagged detection antibody 
resulted in higher background noise that required TIRF microscopy.  b.) TMR-
labeled microtubules functionalized with Anti-BSA IgG and incubated in 100 nM 
TMR-BSA solution. The intensity of the fluorescent signal correlates with the 
fluorescent antigen bound, which is plotted with respect to the conjugation 
conditions. The error bar represents the standard error of each measurement (30 
< N < 80). 
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specific and the antigenicity of our functionalized MTs, a fundamental 
requirement for future immunoassay applications, is preserved.  
In the context of the envisioned applications, it is important to 
characterize the specificity of antigen binding to determine if nonspecific binding 
of antigen to the MT surface will limit antigen detection and ensure that our 
results are applicable to a wide range of antigens. Ideally, nonspecific binding 
would be sufficiently low (characterized by a dissociation constant KD that is 
significantly higher than that of the antibody) such that the specificity (defined 
by the ratio of antigen molecules bound to antibody on the functionalized MT to 
the number nonspecifically adsorbed to the MT surface) would not limit the 
resolution of the assay. To quantitatively measure binding of fluorescent analyte 
to MTs, I quantified the fluorescence intensities from MT surfaces and relate 
these to calibrated intensities (See Figure 3.4). I measured the amount of TMR-
BSA that binds to untreated MTs, which is representative of the nonspecific 
binding of antigen to functionalized MT surfaces. Specifically, I incubated 
untreated MTs with 100 nM, and 1 µM TMR-labeled antigen for 30 minutes and 
then measured the number of rhodamine dye molecules on the MT surface. 
Nonspecific binding was negligible at 100 nM with only 1.7 ± 3.7 BSA µm-1 
(N=27) adsorbing to the MT surface. Nonspecific BSA binding became significant 
only at 1 µM TMR-BSA in solution where unfunctionalized MTs bound 33.8 ± 5.4 
BSA µm-1 (N=49) of MT. The observed adsorption behavior results in a 
nonspecific dissociation constant several orders of magnitude higher than the 
dissociation constant for a typical antibody (10-10 M) and is consistent with low-
affinity, nonspecific protein- protein interactions as observed by others.[124] Since 
 33  
Figure 3.4 Image processing for binding capacity measurements. First, the 
background was subtracted (left). The length and integrated fluorescent intensity 
of MTs labeled with rhodamine at a known labeling ratio were measured to 
determine the standard fluorescence for a single rhodamine dye (top right). The 
same length and fluorescence measurements were done on functionalized MTs 
under the same imaging conditions. From here, I calculated the number of 
rhodamine-labeled antigens on a MT (bottom right).  
 
the ratio of nonspecific to specific analyte binding is <10%in the presence of 100 
nM antigen for anti-BSA and f(Ab)’2 anti-BSA, I can conclude that antigen 
binding is highly specific, and integrating kinesin and microtubules into this 
immunoassay platform does not sacrifice nor interfere with the specificity of 
antibody-antigen binding. 
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To predict the potential these engineered nanoshuttles have in future 
immunoassay applications, I characterized the binding capacity of these 
functionalized MTs. I define the MT binding capacity as the number of antigen 
molecules a MT carries per unit length when all antigen-binding sites on the MT 
are theoretically occupied. To determine the binding capacity, I refer to ligand-
receptor kinetics to ensure that an antigen occupies every antibody in our 
binding capacity assays. The dissociation constant of a typical antibody is !! = !!""!!" ≈ 100  !",  where !!" ≈ 10!  !!!  !"#!!  and !!"" ≈ 10!!  !"#!! .[125] If I 
define R as the concentration of antibody (receptor) in solution, L as the 
concentration of antigen (ligand) in solution, then C, the concentration of bound 
antibody-antigen, is given by  ! + !   ⇄!"##!"# ! 
and the kinetics of our system is  !"!" = !!"!" − !!""!. 
At equilibrium (  !"!" = 0), neglecting the effect of ligand depletion and assuming 
this limit is asymptotically approached for ! ≫ (!!"!!!"#$ + !!"")!!, then !!"#$%$&'$#( = !!"!#$!!"!#$!!!!!"!#$ . 
Binding capacity assays were done with 100 nM antigen and < 0.2 nM antibody 
bound to microtubules in solution. Thus, the conditions of the binding capacity 
assays are conducive to 99.9% of antigen binding sites being occupied after a 25-
minute incubation according to the assumptions stated above. 
Using workable concentrations of crosslinker and anti-BSA antibody, I 
varied the concentrations of SMCC and antibody to maximize the binding 
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density of the conjugation. Binding capacity assays were performed using the 
same protocol used for specificity assays. I achieved a maximum binding 
capacity of 112.6 ± 3.2 antigen molecules per micrometer of microtubule as 
shown in Figure 3.4b. Our data illustrate that optimal, high binding capacities 
depend mostly on using the appropriate excesses of SMCC in the conjugation. 
High excesses (40- and 200-fold excesses of SMCC with respect to total tubulin) 
result in fewer antigens bound to the functionalized MT. At low crosslinker 
concentrations (2-fold excess) I consistently observe low antigen densities on the 
microtubules (1.5 ± 0.72 BSA µm-1 (N=83)), resulting in optimal labeling at 
approximately 8-fold SMCC excess. I also conducted additional measurements 
(data not shown) at intermediate SMCC stoichiometries (10- and 14-fold) that 
showed that the optimum crosslinker concentration for our experimental 
conditions is close to an 8-fold excess, and the antibody density as measured by 
the number of functional antibodies per unit length of microtubule declines 
monotonically from this optimum. I believe that this optimum is the result of two 
of competing mechanisms. At SMCC concentrations below the optimal 8-fold 
excess, the number of tubulin dimers labeled by the amine-reactive group in the 
crosslinker is limited, and consequently, increasing SMCC concentrations led to 
more antibody binding. On the other hand, while high concentrations of SMCC 
activate nearly all tubulin dimers, excess SMCC at increasing stoichiometries are 
practically impossible to completely remove from the MT preparation, and 
unbound reagent in solution reacts quickly with antibodies such that the number 
of antibodies binding to the MT is reduced. While I do see a strong correlation 
between SMCC concentration and binding capacity, the correlation between 
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antibody excesses and binding capacity is not apparent for the range of antibody 
excesses used here. In addition to attaining high binding densities on the MT 
shuttles, another important consideration is that the motility properties of the 
MT-kinesin system remain intact after functionalization and analyte capture. 
 
Motility Properties of Antibody-Functionalized Microshuttles 
Since the kinesin-MT interactions depend on electrostatic and steric 
interactions to sustain motility, there are concerns that heavily functionalizing a 
MT can prevent or impair kinesin motility.[32] To characterize the effect our 
conjugation method has on the motile properties of the kinesin-MT system, I 
measured the speed using gliding assays in the presence of 10 nM analyte (see 
Experimental Section) (Figure 3.5). The kymograph shown in Figure 3.5a shows 
that the quality of gliding assay motility with antibody-functionalized MTs is 
similar to unfunctionalized MTs. Looking at the white columns in Figure 3.5b 
where no antibody is on the MT, I conclude that SMCC excesses have a slightly 
negative effect on gliding assay speeds. I do not see a consistent correlation 
between antibody excesses and gliding assay speed. Steric issues that would 
likely be caused by the large antibody are not a problem as I see only a 33% 
velocity decrease down to 800 nm sec-1 when the MT contains over 100 antibodies 
µm-1 in the 8-fold SMCC 10-fold antibody assay. The SMCC crosslinker appears 
to be sufficiently small as to not terminate motility. Kinesins seem to easily 
accommodate for antibodies, which label only 5-10% of tubulin dimers. The 
conjugation parameters I tested using anti-BSA and TMR-BSA revealed a range 
of conditions where the effects on motility are moderate, and the functionalized 
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Figure 3.5 Functionalized microtubules support motility. a.) Kymograph of a 
microtubule functionalized with anti-BSA in 10 nM TMR-BSA demonstrating 
that kinesin motility is largely unaffected under the conditions used. Frames are 
separated by 2 seconds. b.) Velocity of anti-BSA functionalized microtubules in 
10 nM TMR-BSA solution was measured in gliding assays. The error bar 
represents the standard deviation of each measurement.  
 
MTs are capable of supporting robust gliding assays that can be integrated into 
an active transport system. 
 
Limitations for Sandwich Assay Construct 
Ideally, for diagnostic applications one would prefer to utilize an antibody 
sandwich assay construct that takes advantage of a labeled complementary 
antibody to detect the analyte (See Figure 2.3). Labeling with a second antibody 
is more advantageous than the detection method used in the anti-BSA results 
discussed above because the analyte itself does not need to be directly labeled for 
detection. Directly labeling the analyte specifically without the use of a labeled 
detection antibody is unrealistic for diagnostic applications. Covalent labeling 
proteins relies on generic labeling chemistries that target specific moieties but are 
unable to distinguish between the same moieties on two different proteins. 
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Therefore, to specifically covalently label protein analytes, the analyte must be 
purified from the sample using various chromatography and/or filtration 
techniques and then labeled using these generic labeling chemistries. Purifying 
the sample to specifically label the analyte is necessary to maintain low 
background fluorescence and to eliminate false signals caused by cross-reactive 
species. The yield of such a purification and labeling procedure is generally low 
(<20%), and furthermore, once the protein analyte is purified from the sample to 
be labeled, such an ELISA platform is unnecessary since protein concentrations 
could be determined using other techniques such as absorbance measurements. 
Therefore, using fluorescently tagged secondary or complimentary antibodies for 
analyte detection is the ideal method for detecting protein analytes in ELISA 
assays. 
 My results indicate that there are limitations in incorporating antibody 
sandwich assays into this microtubule-based immunoassay platform with 
regards to motility. Sandwich assays were used to confirm that IL-6 cytokine 
binds to anti-IL-6 functionalized microtubules as see in Figure 3.3a. Figure 3.6 
shows how gliding assay motility is affected as the antibody sandwich is 
assembled for IL-6 detection. As discussed in detail previously and illustrated in 
Figure 3.5, covalently binding the primary antibody and BSA antigen to the 
microtubule surface does not significantly impair gliding assay motility. 
However, attaching a detection antibody significantly affects motility by 
reducing gliding velocity over 3-fold to <500 nm sec-1 and leading to poor quality 
motility.  
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Three parameters were measured to characterize quality of motility. A 
microtubule with poor quality motility is either tethered to the kinesin-coated 
surface or has a ‘floating end.’ Tethered microtubules are not motile, have zero 
velocity, and were not included in velocity measurements. Oftentimes, tethered 
microtubules appear to be twitching on the surface, suggesting that motors are 
making contact with the microtubule but an additional mechanism is preventing 
the microtubule from being propelled forward by the motor. Microtubules with 
floating ends are motile, but one of the microtubule ends is freely diffusing in 
solution while the rest of the microtubule is bound to the kinesin-coated surface, 
which propels it forward (See Figure 4.4). Floating ends contribute to poor 
quality motility because these free ends can lead to the microtubule dissociating 
from the kinesin-coated surface over time. As the quality of motility is reduced as 
the antibody sandwich is assembled, there is also a significant drop in the 
number of events per field of view. Figure 3.6 shows that the percent of motile 
microtubules and their velocities are positively correlated. The percent of 
microtubules with poor quality motility are negatively correlated to the change 
in velocity and percent of microtubules that are motile. In this case, reducing 
microtubule gliding velocity is indicative of the quality of motility deteriorating.  
To determine if the mechanism driving the degradation of motility with 
the sandwich assay construct is steric, additional experiments were done. 
Constructing the full sandwich assay requires several additional flow and rinse 
steps through the assay chamber (See Experimental Section). Using the same 
anti-IL-6 functionalized microtubules with no antigen or secondary antibody, 
flowing through an equivalent amount of motility buffer at the same time points  
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Figure 3.6 Effect of antibody sandwich cargo on kinesin-microtubule gliding 
assay. The velocities at various stages of anti-IL-6 labeling were measured. The 
gliding velocities of microtubules carrying antibodies and antigens are not 
negatively affected. However, once a detection antibody binds to the antigen 
complex, the velocities and quality of motility are severely affected. Error bars 
show standard deviations.  
 
did not decrease the velocity or quality of motility. These results demonstrate 
that the additional time and flow steps used in these experiments do not 
negatively impact the kinesin-coated surface. To ensure that neither the 
secondary antibody nor the TMR-STV has an effect on motility, unfunctionalized 
microtubules were used in the same assay where they incubated with the anti-IL-
6 secondary antibody and then TMR-STV. Neither velocity nor motility quality 
changed in these assays. Based on these results, I conclude that the negative 
impact on gliding assay motility is not caused by the assay itself but is, instead, 
likely caused by steric hindrances brought about by the large sandwich assay 
construct on the microtubule surface. The bulky construct appears to create 
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microtubules that become tethered on the surface. These observations suggest 
that the antibody sandwich construct cannot be effectively incorporated into the 
aforementioned microtubule concentrator device with the current assay 
conditions. The low microtubule densities and inability for these microtubules to 
move processively for long periods of time (50 minutes) prevent a sufficient 
number of microtubules from concentrating to make significant observations. 
The limitations and potential for antibody sandwich assay constructs in kinesin-
driven technologies are further discussed in Chapter 5. 
 
3.4 Conclusions 
The overall goal of this work was to functionalize microtubules with 
antibodies such that they can serve as both an immunoassay substrate and a 
micro-transport mechanism that can bind low concentrations of antigens in 
solution. Our results illustrate that the functionalization method presented here 
specifically binds complimentary antigen from solution and maintains motility. 
An additional advantage is that this method is well suited for a wide variety of 
commercially available antibodies including monoclonal, polyclonal, and f(Ab)’2, 
and it is also compatible with recombinant antibodies. Based on the coupling 
chemistry and the high binding capacity, the technique described in this paper is 
well suited for detecting low concentrations of antigen if directly integrated into 
a microtubule concentrator device such as that developed by Lin et al.[80] Using 
realistic antibody densities established in this work and the device geometry 
reported in our previous work, I estimate that in a 10 nL sample, a total length of 
5 mm of functionalized MTs holding ~100 antibodies µm-1 could capture all of 
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the six antigen molecules found in a 1 fM antigen solution after a 25 minute 
incubation assuming that the antibody-antigen complex has a dissociation 
constant (KD) ≤ 100 pM and the only antibodies in the system are those on the MT 
surface.[80] I believe that the functionalization method developed here holds 
significant potential for sensitive immunoassay applications. By leveraging short 
assay times, sensitivity, the ability to concentrate antigen to lower background 
noise, and retaining antigenicity, these results suggest that the characteristics of 
our functionalized MTs are well suited for advanced, microfluidic immunoassay 
or protein delivery platforms. The next step is to integrate these antibody-
functionalized MTs into an immunoassay platform to extract and detect specific 
proteins from medically relevant samples.  
 
3.5 Experimental Section 
Microtubule Preparation 
Tubulin was extracted from bovine brain using a high salt cycling 
purification protocol and alternate polymerization and depolymerization 
cycles.[126] Microtubules for functionalization and motility assay were 
polymerized in a solution containing 2.0 mg ml-1 tubulin, 4.0 mM MgCl2, 1.0 mM 
GTP, and 5% DMSO in BRB80 buffer (80 mM K-PIPES, 1.0 mM EGTA, 1.0 mM 
MgCl2; pH 6.8). The polymerization solutions were incubated at 37° C for 30 
minutes and then stabilized by diluting the solution 4-fold in a BRB80 and 20 µM 
paclitaxel (LC Laboratories P-9600) solution. Labeled tubulin dimers were 
labeled with amine reactive dyes 5-(and-6)-carboxythetramethylrhodamine 
(Molecular Probes C1171) or cyanine-5 (GE Healthcare, PA15104). Excess dye 
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was quenched with K-glutamate, and microtubules were removed from the dye 
through polymerization and cycling. Labeling ratios of dye to tubulin was 
determined by absorbance measurements (Shimadzu BioSpec) and the Beer-
Lambert law.  
 
Kinesin Purification 
A kinesin motor consisting of the head and neck domain of Neurospara 
crassa kinesin  (amino acids 1-433) and the stalk of Homo sapiens kinesin (amino 
acids 433-560) with a cysteine tag called NKHK560cys was used. Motors were 
expressed and purified as described by Lakamper, et al.[127] Briefly, motors were 
expressed in DH5α Escherichia coli cells and purified using cation exchange 
chromatography (GE 17-5054-01).  
 
Microtubule Antibody Conjugation 
The following buffers were degassed using a vacuum pump and flushed 
with dry nitrogen gas before the conjugation procedure: PBS (100 mM Sodium 
Phosphate, 0.15 M NaCl; pH 7.2), Activation Buffer (100 mM Sodium Phosphate, 
0.15 M NaCl, 10 mM EDTA; pH 7.2), Cushion (0.1M NaHEPES, 1.0 mM MgCl2, 
1.0 mM EGTA, 60% v/v glycerol; pH 6.8). Microtubules were polymerized, spun 
down, and resuspended in PBS containing 20µM paclitaxel (+T).  SMCC 
crosslinker was dissolved in DMSO at 4 mg ml-1, added to microtubules at the 
desired molar excess, and incubated at room temperature for 30 minutes. Excess 
crosslinker was removed from solution by spinning the treated microtubules 
through the cushion +T. SMCC treated microtubules were resuspended in 
 44  
activation buffer +T. Antibodies were reduced in 50 mM 2-Mercaptoethylamine  
(Thermo 20408) in activation buffer for 90 minutes at 37° C. 2-MEA was removed 
from the buffer through buffer exchange columns flushed with nitrogen. 
Reduced antibodies were immediately added to SMCC-MTs at the desired molar 
excess. F(Ab)’2 fragments underwent a pepsin protease digestion (Pierce, 44688) 
and were frozen before used in the assay. Antibodies and microtubules 
incubated at room temperature for 2.5 hours in a nitrogen flushed environment. 
Excess antibody was removed by spinning and pelleting antibody functionalized 
MTs, removing the supernatant containing free antibodies, rinsing the pellet, and 
then resuspending the functionalized MTs in BRB80 +T. 
 
Ellman’s Reagent Assays 
 Ellman’s reagent (Pierce 22582) is a solution that drives a color change 
when it interacts with free maleimide moieties. Dissolve Ellman’s reagent at 4 mg 
ml-1 in Activation Buffer (see above). Prepare samples such that you expect to 
have 0.1-1.0 nmoles of maleimide in solution. Samples should include the 
crosslinker or protein of interest and contain sequential dilutions of cysteine 
(0.0~5.0 nmoles). A standard curve should be done in parallel containing only 
cysteine dilutions. Add 20 µL Ellman’s solution to 100 µL sample and 1 mL degassed 
Activation Buffer flushed with nitrogen. Measure the absorbance of the solution with 
excitation at 412 nm in the spectrophotometer. Plot the absorbance measurements such 
that the number of moles of cysteine is on the x-axis and the absorbance measurement is 
plotted on the y-axis. The control curve should be a straight line with a constant slope, m. 
The maleimide-containing sample of interest will contain a horizontal lag that signifies 
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free maleimide in solution. The point at which the horizontal lag ends and the a straight 
line with slope m continues correlates to the amount (moles) of reactive maleimide in 
solution. 
 
Binding Capacity Assays 
Antibody-functionalized microtubules were allowed to freely diffuse in 
solution with 100 nM analyte unless otherwise stated for 25 minutes. First, a 
precoat of 0.1 mg ml-1 casein in BRB80 was flown through the microfluidic 
chamber and allowed to incubate for 3 minutes. Subsequently, a kinesin solution 
containing 0.05 mg ml-1 casein and 0.12 mg ml-1 NKHK560cys in BRB80 +T was 
introduced into the chamber and incubated for 5 minutes. Then, antibody-
functionalized MTs and analyte were added to the chamber and allowed to 
incubated for 5 minutes followed by a BRB80 +T rinse set consisting of at least 8 
chamber volumes to rinse away free analyte. For IL-6 assays, the labeling 
antibody was flown through and incubated for 1 hour. After washing the 
chamber, rhodamine-labeled streptavidin was flown through in excess and is 
immediately rinsed with five chamber volumes of BRB80 + T. Samples were 
visualized in epifluorescence using a Zeiss Axiovert 200 microscope and Zeiss 
Plan-Neofluar 40x/1.3 oil immersion objective illuminated by a mercury arc 
lamp unless otherwise noted. Image sequences were recorded with a 
Hammamatsu ORCA ER series camera. Quantitative analysis was performed 
using ImageJ software.  
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Motility Assays 
The assay begins with the same surface precoating and kinesin incubation 
sets described for the binding capacity protocol. Motility buffer (2 mM MgCl2, 
0.05 mg ml-1 casein, 0.08 mg ml-1 catalase, 0.1 mg ml-1 glucose oxidase, 10 mM 
glucose, 10 mM DTT, 1mM ATP) containing 10 nM analyte and functionalized 
MTs were incubate for 20 minutes and then flown through the chamber. The 
chamber was sealed and microtubules incubate for 5 minutes before 
visualization.  
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CHAPTER 4 
KINESIN AND MICROTUBULE COMPATABILITY IN 
HUMAN URINE, SALIVA, AND BLOOD PLASMA 
 
Chapter 3 demonstrated that microtubules can be transformed into microshuttles 
to transport specific protein cargos. These findings show that functionalized 
microtubules can serve as useful platforms for advanced immunoassay 
applications. To further advance the kinesin-microtubule system in medical 
diagnostic platforms, one major gap of knowledge in the field must be 
addressed. Understanding how medically relevant samples affect the kinesin-
microtubule system is critical in moving this active transport system into applied 
technologies. In this chapter I will assess the compatibility of the kinesin-
microtubule system in human urine, saliva, and blood plasma. The potential of 
this system in complex, protein rich body fluids will be characterized by its 
ability to bind cargos and move in gliding assays. Conclusions and discussions 
will be framed to relate our results to the current transport requirements kinesin-
driven technologies have.  
4.1 Introduction 
Concerns regarding the kinesin and microtubule system’s motility 
properties being compatible with more complex, protein rich body fluids (such
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as those listed in Table 2) arise because microtubules are not naturally found in 
body fluids including blood serum, urine, and saliva used in immunoassays. 
Therefore, these body fluids are not necessarily compatible to kinesin-
microtubule functionalities, which brings about two main concerns. First, 
protein-rich solutions can be detrimental to the nonnative proteins.[128, 129] 
Incorporating engineered kinesin and chemically stabilized bovine microtubules 
in mammalian body fluids may bring unforeseen complications. For example, 
enzymes such as proteases, which are present in blood serum to clot blood and 
saliva to assist in digestion, can bind and breakdown foreign proteins.[130, 131] 
Second, as sample solutions become more complex and protein-dense, specific 
and nonspecific protein-protein interactions occur more frequently. Specific and 
nonspecific protein interactions can hinder protein function sterically, 
electrostatically, or conformationally. Because gliding assays rely on kinesin 
specifically binding to microtubules and microtubule shuttles need cargos to 
specifically bind to microtubules, steric or electrostatic interferences can be 
detrimental to the system. 
To advance this field in the direction of immuno-based POC diagnostic 
applications, I pioneered studies with the kinesin-microtubule system in human 
urine and saliva samples and examined the effects blood plasma has on the 
kinesin-microtubule system. In the field of POC diagnostic technologies, 
researchers are honing their efforts to develop diagnostic platforms that rely on 
urine and saliva samples instead of blood, which is the current standard for most 
ELISA assays.[93, 94] Consequently, urine and saliva are ideal sample targets for 
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future diagnostic technologies, which is why they are a focus in this study along 
with blood plasma. 
Here, I will assess the ability for cargos to bind to microtubules in human 
urine, saliva, and blood plasma. Then, I will look into how these medically 
relevant samples affect gliding assay motility. Finally, a criterion for assessing 
the compatibility of gliding assays in blood plasma will be developed by looking 
at how motility qualitatively changes in blood plasma and how it affects existing 
kinesin-driven technologies. Further understanding the potential and limitations 
of body fluids in the kinesin-microtubule system will give engineers the 
resources to appropriately design next-generation kinesin-driven immunoassay 
platforms accordingly.  
 
4.2 Biotinylated Microtubules and Their Ability to Bind 
Streptavidin Cargos in Human Urine, Saliva, and Blood 
Plasma 
The ability for analyte to bind to the surface of functionalized 
microtubules is critical for microtubules to serve as cargo-carrying microshuttles. 
As discussed specifically with respect to immunoassay applications in Chapter 3, 
affecting the quality of antigen binding to the microtubule by reducing the 
affinity of the antibody, sterically blocking the antigen binding domain, or not 
having sufficient time for the antigen to bind will negatively impact the antigen 
capturing capabilities of the system. Therefore, it is important to properly 
characterize the effect body fluids have on the ability for analyte to bind to 
functionalized microtubule surfaces to conclude if microtubule-based 
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microshuttles can be effectively integrated into immuno-based diagnostic 
platforms. 
 The affinity of antibody-antigen binding is dependent on a number of 
factors including pH, ionic strength, and temperature of the sample. While these 
factors vary across biological samples (See Table 2), antibodies can be engineered 
to be compatible with a variety of samples retain affinities relevant for ELISA 
applications (10-12-10-9 M).[125] The antigenicity of most commercially available 
antibodies to their antigen are generally considered unaffected by medically 
relevant samples such as blood, saliva, and urine.[125] One exception would be 
highly engineered antibodies, typically expressed in bacteria or yeast cultures, 
with high affinities (10-15-10-12 M) that require more controlled and specific buffer 
conditions to capture very small quantities of antigen.[132] Since standard, 
commercially available antibodies are typically used in ELISA, I continue this 
study under the assumption that antibodies themselves are not a limiting factor 
when microtubules are functionalized as an immunoassay substrate.  
To test the effect human urine, saliva, and blood plasma have on the 
ability of functionalized microtubule to bind cargos, I measured the binding of 
rhodamine labeled streptavidin binding to biotinylated microtubules in these 
body fluids and compared the behavior to STV binding to biotinylated MTs in 
BRB80 buffer. I chose to work with biotinylated MTs instead of antibody 
functionalized MTs so that I could more comprehensively assess the magnitude 
of proteins nonspecifically binding to and blocking the microtubule surface. 
Biotin is very small compared to an antibody (0.24 kDa versus 150 kDa, 
respectively). Working with a physically smaller receptor protein, I was able to 
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examine the effects body fluids have on the microtubule surface at a smaller 
scale. For example, if a cytokine, typically 12 kDa in size, nonspecifically binds to 
the microtubule surface, it is more likely to sterically hinder a streptavidin from 
binding to a blocked biotin site that lies very close to the microtubule surface 
than an antigen from binding to an antibody whose binding site lays several 
nanometers away from the microtubule surface. Also, since the biotin-
streptavidin linkage has been an instrumental method in conjugating various 
cargos to microtubules (See Chapter 2), characterizing the effect of body fluids on 
the biotin-streptavidin linkage is also critical in further developing this 
microtubule-based microshuttle system. 
To characterize the ability for the biotinylated microtubule to bind 
streptavidin, I performed binding assays similar to those carried out in Chapter 
3. The assays were done in microfluidic chambers constructed form microscope 
slides and coverglasses. First, I sequentially coated the chambers with buffer 
solutions containing biotin-free casein and NKHK560cys kinesin that adsorbed to 
the glass surfaces. This process was optimized to reduce nonspecific binding of 
free TMR-streptavidin to the glass surface during the assays. In addition, when 
MTs were introduced into the microfluidic chambers, they bound to kinesin 
motors (specifically the N-terminal motor domains) attached to the glass surface, 
and the microtubules were held nanometers from the glass surface for imaging. 
Biotinylated MTs were polymerized such that 93% of the tubulin was 
biotinylated (See Experimental Section) and then pelleted in an airfuge at 30 psi 
for 30 sec and resuspended in buffer containing 20 µM paclitaxel. Spinning down 
the microtubules removed excess biotin remaining from the labeling procedure 
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and biotinylated tubulin that was not polymerized. Once the MTs were bound in 
the microfluidic chamber, the chamber was washed with 5 chamber volumes of 
buffer to remove any remaining free biotin. Then, TMR-streptavidin dilutions 
were made in the body fluid being studied with an addition of 20 µM paclitaxel. 
The streptavidin-containing solution was added to the chamber and incubated 
for 10 minutes with the biotinylated MTs. Lastly, the chamber was washed at one 
time with 15 chamber volumes of buffer plus paclitaxel, and the TMR-
streptavidin-coated MTs were imaged.  
The binding capacities of the biotinylated microtubules were calculated 
using the same image processing technique discussed in Chapter 3 (See Figure 
3.4). All of the imaging was done in BRB80 buffer instead of the body fluid of 
interest. The quantum yield of the dye, which is affected by buffer conditions, 
was not significantly altered by the exposure to body fluids. Control 
measurements were done to quantify the effect the binding assay protocol with 
the three body fluids has on the fluorescence of rhodamine. These results show 
that the maximum change in fluorescent intensity is 20%, which is within the 
range of the standard deviation (±10%) for the measurement. The variance of the 
fluorescent intensity is taken into account in the y-error plotted below in Figure 
4.1.  
Binding assay results are shown in Figure 4.1. This data serves as a 
comparative analysis that illustrates the ability of the microtubule surface to be 
accessible to and bind medium sized proteins (specifically, the 60 kDa 
streptavidin). First, in Figure 4.1a we confirm that TMR-streptavidin binding is  
	   53 
 
Figure 4.2 Microtubules binding TMR-streptavidin cargos in body fluids. a) 
TMR-STV binds specifically to biotinylated MTs in buffer. TMR-STV binds to 
biotinylated microtubules at similar densities while in solutions of 100% b) 
human saliva, c) human urine, and d) blood plasma. 
 
specific to the biotinylated microtubules. The binding affinity of streptavidin to 
biotinylated tubulin in BRB80 buffer is at least an order of magnitude larger than 
streptavidin to unlabeled tubulin. Looking at the 100 nM and 1 nM 
measurements for all samples tested (See Figure 4.1b-d), TMR-streptavidin binds 
to the microtubule surface at densities of one hundred to tens of molecules per 
micron of microtubule, respectively. Thus, the affinities between the biotinylated 
tubulin and streptavidin are similar in all four buffer and human sample assays 
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because !! = !" [!"#][!"!!"#] − [!"] where KA is the affinity, [Bt] is the concentration of 
biotin in solution, [STV] is the concentration of TMR-streptavidin in solution, and 
[Bt-STV] is the measured amount of TMR-streptavidin bound to the microtubule 
surface in solution. Since the binding densities are similar in all four samples 
while the rest of the assay conditions remain constant, I conclude that these body 
fluids allow cargos to bind to the microtubule surface.  
While streptavidin and avidin are not present in human body fluids, 
biotin is inherently found in some body fluids. Free biotin will affect the binding 
capacity measurement by saturating the biotin-binding sites on streptavidin, 
which prevents the biotin-saturated streptavidin from binding to biotinylated 
microtubules. Urine and blood plasma inherently contain high concentrations of 
biotin (on the order of 100 pM and 1 pM, respectively) highlighted in Figure 4.1c 
and d.[115, 133] Since each streptavidin binds four biotin molecules and the affinity 
between biotin and streptavidin is high, the depletion of biotin binding sites on 
streptavidin becomes relevant to the assay when the concentration of 
streptavidin approaches one fourth the concentration of biotin. As expected, the 
binding of free biotin saturates the rhodamine signal in urine and blood plasma, 
resulting in fewer fluorescent streptavidin bound to the microtubule surface at 
low (<100 pM) streptavidin concentrations.  
These results show that 100 nM and 1 nM concentrations of streptavidin 
bind to biotinylated microtubules similarly in plain buffer, undiluted human 
saliva, urine, and blood plasma.  Since the body fluids tested here neither 
sterically nor electrostatically prevent the medium sized streptavidin protein 
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from binding directly to the microtubule surface, I conclude that microtubule 
surfaces are capable of binding cargos in these medically relevant samples that 
are often used in point of care diagnostic tests. These observations corroborate 
the compatibility of antibody-functionalized microtubules as cargo-carrying 
microshuttles in human urine, saliva and blood plasma. Next, I looked into the 
motility properties of microtubules in these medically relevant biological 
samples. 
 
4.3 Microtubules and Their Motility Properties in Blood 
Plasma, Urine, and Saliva 
To investigate the transport capabilities of the kinesin-microtubule system 
in medically relevant samples, I performed gliding assays in a series of dilutions 
of blood plasma, urine, and saliva and measured their velocities. The assay 
chambers were prepared as previously described with a casein coat blocking the 
surface and NKHK560cys kinesin motors adsorb to the glass surface. 
Fluorescently labeled microtubules were introduced into the chamber with an 
ATP-containing motility solution (See Experimental Section) and the body fluid. 
At 87% body fluid the entirety of BRB80 buffer typically used in gliding assays 
was replaced with the body fluid. The remaining 13% of the solution consisted of 
microtubules and motility solution (2 mM MgCl2, 0.05 mg ml-1 casein, 0.08 mg ml-
1 catalase, 0.1 mg ml-1 glucose oxidase, 10 mM glucose, 10 mM DTT, 1 mM ATP, 
20 µM paclitaxel). The microfluidic chambers were then sealed and visualized 
after 10 minutes. The gliding assay results are presented in Figure 4.2 where  
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Figure 4.3 Gliding assay velocities in body fluids. Gliding assay results show 
that gliding assay motility deteriorates at concentrations >27% in human blood 
plasma (top) and saliva (middle). Gliding assay motility remains robust in urine 
(bottom). 
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velocities and kymographs of motile microtubules are presented for each body 
fluid tested. Gliding assay motility was the most robust in human urine while 
gliding assay velocities decrease in higher concentrations of blood plasma and 
saliva. Both plasma and saliva assays show that gliding assay motility stops at 
67% and 47% buffer replacement, respectively, and microtubules no longer bind 
to the kinesin-coated surface. For these assays, the velocity is marked as 0 µm sec-
1 with no error bars because there were no motile events to measure. When blood 
plasma and saliva make up 27% of the motility assay buffer, gliding assay 
velocities decrease significantly by 30-40%. For gliding assays performed in 
urine, there is no marked decline in gliding assay velocity as the urine becomes 
more concentrated in solution.  
As discussed in Chapter 3, gliding assay velocities several hundred 
nanometers per second remain in the ideal range for existing kinesin-driven 
technologies. From these results I conclude that blood plasma, saliva, and urine 
all support gliding assay motility after moderate (< 10-fold) dilutions 10 minutes 
into the gliding assay. These results coupled with the streptavidin-binding 
results presented in Section 4.2 strongly suggest that human saliva, urine, and 
blood plasma can be diluted in assay buffer and directly used without any 
additional processing steps to collect and transport cargos in gliding assays. 
 
4.4 Motility Characteristics Required for Steering 
Microtubules in Kinesin-Driven Technologies 
Now, I will assess the potential of incorporating body fluids in existing 
kinesin-driven technologies. Reflecting on the existing kinesin-driven platforms 
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that have been developed (See Chapter 2), we recall that current designs rely on 
gliding assay geometries where microtubules are autonomously guided through 
microfluidic devices. The most developed kinesin-driven platform(s), such as 
those developed by Lin et al, depend on mechanical microtubule-barrier 
interactions to direct the leading end of microtubules.[72, 79, 80] Another proof-of-
concept models developed by van den Heuvel et al steer the leading end of 
microtubules using electrostatic forces.[89] Both of these steering mechanisms rely 
on guiding the freely diffusing, leading end of the microtubule along a kinesin-
coated surface (See Figure 2.3).[72] To be successful, the devices also require that 
microtubules move and be directed independently of each other and that the 
assay functions for approximately 1 hour.  
To characterize the quality of gliding assay motility, I monitored behaviors that 
were present in body fluid-containing gliding assays and would prevent the 
microtubule tip from being effectively guided in kinesin-driven technologies. 
These behaviors are illustrated in Figure 4.3 and 4.4. I define high quality 
motility as microtubules gliding with constant velocities where the leading end 
of the microtubule is within 600 nm, or within the depth of focus of the optical set 
up (Zeiss Plan-Neofluar 40x/1.3 oil immersion objective excited with 590nm 
light), of the kinesin-coated glass surface as illustrated in the top panel of Figure 
4.3. High quality motility is the most ideal for the microtubule tip to be 
effectively guided in kinesin-driven platforms because steering events have a 
higher probability of success and is the standard upon which existing 
microtubule-guiding models are based.[72]  
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Figure 4.4 High quality motility and the effects of aggregation. Top High 
quality, smooth motility is conducive for leading MT tips to be effectively guided 
mechanically in gliding assays. Bottom Moderate MT bundling prevents MTs 
from being independently guided in kinesin-driven technologies. Severe 
aggregation halts MT motility in gliding assays. 
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Microtubules aggregating was an artifact observed in certain assays 
containing body fluids. While bundled microtubules can still remain motile as 
seen in the kymograph labeled “Moderate” in the bottom pane of Figure 4.3 and 
in existing literature, individual microtubules cannot be distinguished and 
independently guided in assays where individual MT control is necessary for 
successful steering events.[134] Bundling can become more burdensome in assays 
by causing microtubule aggregates that are not parallel to each other as seen in 
the kymograph labeled “Severe” in the bottom pane of Figure 4.3. Severe 
bundling prevents MTs from moving in a gliding assay, and over time, these 
severe bundles dissociate from the kinesin-coated surface and diffuse away. 
Halting motility in a gliding assay and having microtubules dissociate from the 
kinesin-coated surface due to severe clumping is detrimental to the kinesin-
driven technologies that characterize success as moving microtubules 
throughout a microfluidic platform. Others have explained microtubule 
aggregation as an artifact of either specific or nonspecific protein-protein 
interactions.[135-137] Specific protein-protein interactions that cause MT bundling 
usually involve microtubule-associated proteins (MAPs) or microtubule-based 
biomolecular motors. When bundling occurs in solutions that do not contain 
MAPs or MT-based motors, such as the body fluids used in these assays, we 
assume that nonspecific protein-protein interactions cause the aggregation. 
Figure 4.4 illustrates a third artifact of gliding assays in body fluids called 
floating ends. Floating ends are not typically seen in motility assays performed in 
popular buffer conditions and have not been previously studied. Since floating 
ends are not prevalent in standard gliding assays, I assume that the floating ends 
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are an artifact of the protein-rich samples and not a result of imperfections in the 
microtubule that may cause curvature at the ends. A floating end occurs when 
one end of a microtubule dissociates from the kinesin-coated surface and diffuses 
hundreds of nanometers to microns into solution. “Moderate” floating ends 
diffuse into solution, eventually reattach, and continue to glide upon to the 
kinesin-coated surface. The yellow arrow in the kymograph marks the point 
where the microtubule detaches from the kinesin-coated surface and the floating 
end begins to the right of this point. Floating ends are considered “Severe” when 
the microtubule completely dissociates from the kinesin-coated surface and 
diffuses into solution which is not ideal for microtubule shuttles transporting 
cargos in kinesin-driven devices. 
While MTs exhibiting moderate floating ends continue to be motile, the 
floating end reduces the probability of a successful steering event because of the 
mechanics of the system. Microtubules are naturally stiff with a persistence 
length of 8 millimeters.[138] Since microtubules typically used in gliding assays are 
tens of microns long, we can assume that a microtubule acts as an elastic 
cylindrical rod.[138] When bound to a kinesin-coated surface, it is energetically 
favorable for the stiff microtubule to remain bound to the flat, glass surface (xy 
plane). The leading tips of microtubules in gliding assays undergo thermal 
diffusion (Figure 2.3) such that the tip diffuses in solution at some angle θ in the 
z-direction. In smooth, high quality motility θ remains very small, and the freely 
diffusing end of the microtubule quickly binds to a kinesin motor molecule in the 
directed path to be successfully guided. In high quality motility, the elastic 
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Figure 4.4 Floating ends are detrimental to guiding microtubules The yellow 
arrow marks where the floating end begins. In both kymographs the floating end 
is to the right of the arrow and diffuses freely in solution while the remainder of 
the MT stays bound to the kinesin-coated surface. In moderate cases, the MT can 
sustain gliding assay motility. Severe floating ends cause the MT to dissociate 
from the kinesin-coated surface.  
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energy due to bending is U(θ) >> kBT where kB is the Boltzmann constant and T is 
the temperature. 
As a result, the restoring force overpowers thermal fluctuations and drives 
the stiff microtubule down to the kinesin-coated xy-plane (θ = 0), assuming that 
kinesin is sufficiently dense and is not a limiting factor. When θ becomes larger 
and approaches some critical angle β(θ), the restoring force that drives the MT 
down to the more energetically favorable position (θ = 0) for successful steering 
events can be overpowered by a drag force on the MT tip. By definition, θ for 
MTs with floating ends is significantly larger than θ in high quality motility. 
Thus, floating ends increase the probability for microtubule tips to reach 
microstates where θ ≥ β(θ), which increases the probability of having 
unsuccessful steering events and is undesirable for kinesin-driven technologies. 
Two theories of the causation of floating ends are addressed here. First, 
floating ends can be an artifact of a sparsely coated kinesin surface. Defining tk as 
the time it takes the MT tip to bind to the next kinesin molecule, if !! > ! ! where 
l is the length of the portion of the microtubule bound to the kinesin-coated 
surface and v is the gliding velocity of the microtubule, then a floating end 
would be considered “severe” and the MT would dissociate from kinesin-coated 
surface. According to previous literature, I assume that kinesins are spaced 
approximately 200 nm apart from one another in the assays used in this work. 
This kinesin-density has been shown to promote smooth, high quality motility 
under typical assay conditions.[72] An alternative theory for the cause of floating 
ends is that proteins block the microtubule surface such that kinesin cannot 
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successfully bind to the microtubule surface. This would result in severe floating 
ends if protein blocking made tk such that !! > ! !.  Functionally, the two effects 
are the same.  
To better understand the potential of the kinesin-microtubule system in 
advanced immunoassay platforms, I performed an in depth analysis to 
characterize gliding assay motility using the three qualitative standards of 
motility established in this section in blood plasma, specifically. By 
understanding the effects blood plasma has on gliding assay motility, we can 
prepare samples accordingly and engineer devices to develop robust, efficient 
kinesin-driven devices that function in medically relevant samples. 
 
4.5 Motility Properties of Kinesin and Microtubules in 
Human Blood Plasma 
To assess the compatibility of blood plasma for kinesin-driven 
technologies, I measured the gliding speeds and the amount of bundling and 
floating end events that occurred in gliding assays. By tracking the number of 
MTs that remain motile and can be guided independently (i.e., no clumping or 
bundling) and efficiently via the leading end being conjugated to the kinesin-
coated surface (i.e., no floating ends) over 1 hour, I can determine under which 
conditions blood plasma can be successfully incorporated into kinesin-driven 
technologies that autonomously steer microtubules. These gliding assays were 
performed using NKHK560cys motors, fluorescently tagged microtubules, and 
the same assay conditions as previously mentioned (See Experimental Section). 
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Since assays were monitored for one hour, an ATP regeneration system was 
incorporated into the motility buffer to ensure that changes in velocity were an 
effect of the blood plasma in solution and not due to depletion of ATP.  
 
Unfiltered Blood Plasma 
Gliding assay motility results are illustrated in Figure 4.5 where blood 
plasma made up 5%, 1%, and 0.1% of the motility buffer. The gliding assay 
velocities were unaffected by the presence of blood plasma during the one hour 
assay (grey bars). The velocities remain constant throughout the assay, staying 
within one standard deviation of the initial velocity. The phosphokinase ATP 
regeneration system used is sufficient for maintaining robust gliding assay 
motility in solutions containing 5% blood plasma. Since no change in velocity is 
seen as the concentration of blood plasma increases by 50-fold in this assay, it 
appears that the kinesin motor molecules themselves are unaffected by the 
presence of blood plasma in the sample. Significant inhibitiors or steric or 
electrostatic interferences between kinesin and proteins in the blood plasma 
would have the following effects: increase in the presence of floating ends, 
slower gliding assay velocities, or terminate the gliding velocity. Since 
microtubule behavior is observed in this assay, directly drawing conclusions 
regarding the kinesin in the system would not be compelling or sound. To assess 
the effect blood plasma has on kinesin motor molecules, one could make single 
molecule observations to determine how the binding rate, velocity, and run 
length of kinesins are effected in blood plasma when compared to plain assay  
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Figure 4.5 Gliding assay motility in blood plasma Gliding assay velocity (grey 
bars) remain constant in the presence of blood plasma. MT clumping (pink) 
affects the 5% plasma assay while floating ends significantly affect 1% and 0.1% 
assays after 60 minute long assays. 
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buffer. Due to the complexity of the blood plasma, it would be difficult to 
distinguish whether the quality of motility is affected by plasma proteins 
interfering with the microtubule surface or the kinesin motors themselves. 
Although diagnosing the exact mechanism affecting the system is limited in both 
gliding and single molecule assays, interpreting gliding assay results is the most 
appropriate method to assess the kinesin and microtubule’s compatibility in 
blood plasma for kinesin-driven technologies that rely on gliding assay protein 
geometries.  
Next, I look at how blood plasma affects the quality of microtubule 
gliding by observing detrimental behaviors outlined in Section 4.4. Shown in 
Figure 4.5 MT bundling (pink circles) is significant in the more concentrated 5% 
assays with 66% of the MTs being clumped or bundled after an hour. As MT 
aggregation becomes an issue in the 5% blood plasma assay, the ratio of motile 
MTs in the assay remains high. Over time, severely bundled MTs dissociate from 
the kinesin-coated surface and diffuse away. As bundling progresses in the 5% 
assay, only those that are still motile are present in these observations (green 
circles). In the 1.0% and 0.1% assays floating ends lower the quality of motility 
more so than aggregation. As 100% of the microtubules in the assays have 
floating ends within 40 to 60 minutes in the 1% and 0.1% blood plasma assays, 
respectively, the motility ratios (green circles) in the gliding assay decline. The 
1% and 0.1% assays have more MTs tethered to the glass surface that are not 
motile.  
 These results corroborate that blood plasma interferes with the 
mechanisms utilized in existing kinesin-driven technology platforms that rely on 
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steering microtubule tips. Because bundling dominates in the higher (5%) blood 
plasma concentrations, this data suggests that nonspecific protein-protein 
interactions affect the quality of gliding assay motility. The fact that the velocities 
in 1% and 0.1% blood plasma assays do not decrease suggests that the floating 
ends in these assays are an artifact of more moderate protein-protein interactions 
(instead of direct kinesin interference) which would be a direct result of further 
diluting the blood plasma from 5% where protein-protein interactions cause 
bundling. Preliminary experiments integrating 1% blood plasma into Lin’s 
microtubule concentrator device, and these conclusions were confirmed. 
Microtubules on the kinesin-coated surface were motile, however the density of 
the microtubules in the devices significantly decreased with time. As 
microtubules encountered the kinesin-free barriers, they dissociated from the 
kinesin-coated surface instead of being steered by the barrier. The number of 
MTs concentrated in 1% blood plasma was <1% of those concentrated in plain 
assay buffer. The few that were concentrated consisted of motile microtubule 
bundles that successfully made their way to the concentrator regions. 
Significant (1,000-fold) dilutions of plasma are not sufficient in sustaining 
long term (1 hour) motility assays that rely on steering microtubules because of 
the abundance of floating ends. Thousand-fold sample dilutions themselves are 
not ideal for immunoassay applications regardless of the motility effects because 
diluting the sample demands more sensitive detection capabilities. To exhaust 
the studies on the blood plasma for the proposed technologies, I looked into 
sample preparation techniques that result in high quality motility and are 
applicable for point-of-care diagnostic applications to which kinesin are so 
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appealing. In immunoassays a large number of biomarkers commonly used for 
disease detection involve a class of small molecular weight proteins called 
cytokines.[139] In order to keep cytokines of interest in the blood plasma sample 
and limiting the protein-protein interactions that likely interfered with the blood 
plasma gliding assay, I filtered the blood plasma using size exclusion filtration. 
 
Filtered (10 kDa) Blood Plasma 
 Filtering blood plasma with a 10 kDa filter keeps 10% of the protein 
species and 74% of the hormone species that are inherently found in blood 
plasma present in the sample, which is ideal for immunoassays that detect an 
array of these small proteins, peptides, or steroids. The 10 kDa filtration step also 
keeps small molecule drugs in the blood sample which can be monitored to 
determine the effectiveness or status of various drug delivery systems such as 
chemotherapies. After filtration the blood plasma was used immediately in the 
same gliding assay protocol (See Experimental Section). The microtubule 
velocity and quality of motility were analyzed using the same set of qualitative 
standards discussed in Section 4.4. I tested 10-, 20-, and 100- fold dilutions of 
filtered blood plasma. Similar to the unfiltered plasma, the gliding assay 
velocities in filtered plasma were unaffected by the tested dilutions. The 
velocities for all of the tested samples were constant for one hour, all ranging 
within one standard deviation of the measurement. Since the unfiltered blood 
plasma did not alter the gliding assay velocity (See Figure 4.5), I expected that 
filtering plasma and removing proteins from the solution would either glide  
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Figure 4.6 Gliding assay motility in 10 kDa filtered blood plasma. Gliding 
assay velocities (grey bars) are not significantly affected by incorporating filtered 
blood plasma in gliding assays. As time increases, floating end MTs impact the 
quality of motility in 10% and 5% samples while MT bundling is not an issue 
when compared to unfiltered blood plasma.  
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similarly or more robustly than in unfiltered plasma. Filtering out large proteins 
and ultimately reducing the total protein concentration in solution led to a 
significant decrease in microtubule bundling or aggregation (pink circles) where 
>87% of the microtubules in solution were gliding independent of each other. 
Additionally, the presence of floating ends (yellow circles) was significantly 
reduced in the filtered sample. After one hour floating ends make up 27%, 9%, 
and 5% of the 10-, 20-, and 100-fold diluted plasma samples, respectively. As 
hypothesized, reducing the concentration of plasma protein in the assay led to 
higher quality motility. These observations support the theory that bundling and 
floating ends are caused by nonspecific protein-protein interactions. As the 
quality of motility improves by filtering the blood plasma, the ratio of motile 
microtubules also increases. 
 
4.6 Conclusions 
 The results presented in this Chapter indicate that microtubules can 
collect and transport cargos in human saliva, urine, and blood plasma for short 
(10 minute) time scales. I developed a method to analyze the compatibility of 
complex biological samples in existing kinesin-driven technologies that rely on 
controlling microtubule motion by steering the leading tip of the microtubule in 
gliding assays. After assessing the quality of motility in blood plasma and 10 kDa 
filtered blood plasma, I concluded that unfiltered blood plasma is not an effective 
sample to incorporate in such assays. To achieve high quality motility in 
unfiltered blood plasma, assays must be done for short periods of time (<1 hour) 
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and diluted 1000-fold. These large dilutions negate the benefits of performing 
immunoassays in blood plasma because the analyte of interest becomes diluted 
1000-fold and detection limits of immunoassay platforms must compensate by 
becoming 100- or 1000-fold more sensitive for most assays. Robust motility that 
satisfies the current demands of kinesin-driven technologies is achieved through 
a 10- to 20-fold dilution of blood plasma that contains the proteins, peptides and 
steroids 10 kDa or smaller.   
 
4.7 Experimental Section 
Human Sample Preparation: Blood Plasma 
Blood was drawn in a sterile environment from a trained professional per 
OSEH regulations in an EDTA anticoagulant coated tube (Becton Dickinson 
367861). Tube was inverted several times. Blood was spun for 15 minutes at 2,000 
x g at 4° C to remove blood cells and platelets. Supernatant was put in a clean 
tube and kept on ice until it was aliquoted and frozen at -80° C for storage. Blood 
plasma was thawed on ice before each assay and vortexed for several seconds 
before handling. When blood plasma samples were filtered, pure blood plasma 
was spun for 15 minutes at 5,000 x g in 10 kDa columns (Corning Spin-X) or 30 
kDA columns (Amicon). The solution that was filtered out of the columns was 
used immediately and considered the 100% filtered plasma standard. 
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Human Sample Preparation: Saliva 
No food or liquid was consumed 1 hour prior to collecting the saliva 
sample. After collection, saliva was spun at 10,000 x g for 20 minutes at 4° C. The 
supernatant was collected, aliquoted, and stored at -80° C. Saliva was thawed on 
ice before each assay and vortexed for several seconds before handling. 
 
Human Sample Preparation: Urine 
Urine was collected and centrifuged at 10,000 x g for 20 minutes at 4° C 
and then filtered through a 0.22 µm vacuum filter. The sample was then 
aliquoted and stored at -80° C until used in the assay. Urine was thawed on ice 
before each assay and vortexed for several seconds before handling. 
 
Microtubule Preparation  
Tubulin was purified and microtubules were polymerized as described in 
Chapter 3.[126] In the binding assays, tubulin was labeled with amine-reactive 
biotin-XX succinamadyl ester (Thermo B-1606) using the same labeling 
procedure used for TMR dye described in Chapter 3. Excess biotin was quenched 
with K-glutamate, and microtubules were removed from the label through 
polymerization and cycling.  
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Binding Capacity Assays  
Microtubules polymerized with 1.87 mg ml-1 biotinylated tubulin and 0.13 
mg ml-1 tetramethylrhodamine labeled tubulin. After polymerization, 
microtubules were spun in Beckman Airfuge at 30 psi for 30 seconds and 
resuspended in BRB80+T. Tetramethylrhodamine streptavidin (Invitrogen S-870) 
was carefully diluted for this assay as to ensure that a significant amount of 
protein was not lost to nonspecific binding of the streptavidin to the surface of 
the eppendorf tubes or pipette tips. Dilutions were done in a solution of 1.0 mg 
ml-1 biotin-free casein that will be referred to as blocking buffer. For human 
sample assays, dilutions were done using the same protocol except that the 
protein-rich human sample was used as the blocking buffer. The desired amount 
of blocking buffer was added to the base of the tubes in which the dilution took 
place and allowed to sit for several minutes to ensure that the surface of the tube 
was blocked. Pipette tips were coated with the blocking buffer before pipetting 
any solution containing streptavidin. Once streptavidin was added to the 
dilutions, the solution was mixed using a blocked pipette tip in the base of the 
tube coated with blocking buffer.  
All assays were performed in a microfluidic chamber described in Chapter 
3. First, a precoat of 0.1 mg ml-1 casein in BRB80 is flown through and sits for 3 
minutes. Kinesin wash containing 0.05 mg ml-1 casein and excess NKHK560cys in 
BRB80 +T is flown through and sits for 5 minutes. Biotinylated microtubules 
were flown through and sit for 5 minutes followed by a BRB80 +T rinse of 5 
chamber volumes to rinse away any remaining free biotin. Two chamber 
volumes of TMR-streptavidin diluted in blocking buffer or the human sample 
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being tested was flown into the chamber and incubated with the microtubules 
for 10 minutes. The free, unbound fluorescent streptavidin was rinsed from the 
chamber using 15 chamber volumes of BRB80+T. Samples were visualized using 
the aforementioned epifluorescence, mercury arc lamp optical set up. Image 
processing and measurements were done using the same protocol discussed in 
Chapter 3. 
 
Motility Assays  
Microfluidic flow chamber was assembled as described above. The assay 
begins with the same precoat and kinesin wash described above for the binding 
capacity protocol. Motility buffer (2 mM MgCl2, 0.05 mg ml-1 casein, 0.08 mg ml-1 
catalase, 0.1 mg ml-1 glucose oxidase, 10 mM glucose, 10 mM DTT, 1 mM ATP, 20 
µM paclitaxel) containing TMR-labeled microtubules and an ATP regeneration 
system (0.05 mg ml-1 creatine phosphokinase and 10 mM phosphocreatine) was 
added to the specific human samples and then flown through the chamber. 
Dilutions of the human samples were made in BRB80 such that only the human 
sample itself is diluted from the solution and enzymes and chemicals (with the 
exception of BRB80) within the motility buffer remain at constant concentrations. 
The chamber is sealed with hot wax and sits for 5 minutes before visualizing. 
Image sequences were taken on the aforementioned optical set up. 
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Quality of Motility 
Motility assays were run as described above. Data was collected in 10 
frames with 2 seconds between each frame at the mentioned time intervals. The 
videos were analyzed by eye where each event was counted during the 20 sec 
clip. Tethered or floating events included any event that did not move or had a 
floating end for at least 6 seconds. The total number of microtubules observed 
were those counted in the first frame and used as the total number of MTs 
throughout the entire analysis for that 20 sec video.   
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CHAPTER 5 
 
CONCLUSIONS AND FUTURE WORK 
 
The work presented in this dissertation makes a clear step forward in the 
direction of implementing a kinesin-driven active transport system into a 
realistic immunoassay platform to detect ultralow analyte concentrations. This 
progress is promising for the implementation of such a device in resource-
limited settings where assays must be done quickly with noninvasive samples 
and without electricity at ambient temperatures. Before a kinein-microtubule 
based immunoassay platform can be implemented in clinical settings there are 
two key barriers that must be overcome. Here, I will discuss the necessary future 
steps to detect analyte that is not directly labeled (Section 5.2) and in better 
incorporating the microtubule-kinesin system into medically relevant samples 
(Section 5.3). The section will conclude with suggestions for future directions 
kinesin-driven systems should progress. 
 
5.1 Conclusions 
 The work presented in this thesis critically contributes to the field of 
biomolecular motor-driven technologies. While scientists and engineers have   
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developed the kinesin-microtubule system to serve as an active transport system 
for LOC technologies, there existed voids in previous work that prevented the 
system from being implemented into clinical settings, specifically a more 
thorough, quantitative analysis assessing the detection potential of antibody 
functionalized microtubules and the compatibility of the protein systems in 
medically relevant samples. In this work a protocol was developed to covalently 
link antibodies to microtubules that was designed to prevent undesired 
crosslinking events which results in simple handling procedures, faster assay 
times, and cheaper assays. Furthermore, the antigen binding capabilities of the 
functionalized microtubules were thoroughly quantitatively analyzed to 
conclude that microtubules could, in fact, be used to capture ultralow (fM) 
concentrations of antigen. The second portion of this work looked at the ability 
for microtubules to bind cargos and be transported in gliding assays in human 
blood plasma, urine, and saliva. The results show that microtubules can, in fact, 
capture and transport cargos in these medically relevant samples. A set of 
criterion was established to characterize the effect body fluids have on gliding 
assays that is reflective of the demands for current kinesin-driven technologies. 
The method of analysis should serve as a standard for future kinesin-
microtubule-body fluid compatibility studies as it gives a unique insight to the 
potential the body fluid has on being integrated into kinesin-driven technologies. 
The quantitative analyses performed throughout this dissertation work 
are novel and were necessary in establishing the kinesin-microtubule system as a 
platform for immunoassays. Here, I will address the future work that needs to be 
done in developing an ELISA-based device that takes advantage of the kinesin-
microtubule system that is ready for clinical use. I begin by exploring the work 
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needed to broadly detect and transport antigen labeled with a detection 
antibody. Then, the necessary engineering that needs to be done to create a 
micro- or nanofluidic device that harnesses the body fluid motility results 
presented will be discussed.  
  
5.2 Future Work: Fluorescent Detection Via Labeled 
Detection Antibodies  
 
As addressed in Chapter 3 a thorough study exploring gliding assay 
motility with antibody-sandwich constructs tethered to the microtubule surface 
should be explored to most effectively implement the antibody functionalized 
MTs into clinical settings. The assays in this dissertation demonstrated robust 
motility when antibodies tethered to MTs were carrying fluorescently tagged 
antigens. In clinical settings, labeling the antigen directly is unrealistic. If one 
were to specifically label the antigen, which would require purifying the protein 
from the sample, the immunoassay itself would become unnecessary since the 
protein would be extracted through other means. Using a fluorescently tagged 
detection antibody to specifically label the antigen is the current standard for 
immunoassays and is ideal. In this study I discovered that the large antibody 
sandwich constructs present in high densities sterically hinder the microtubule-
kinesin interaction in the given assay conditions, which prevents gliding assay 
motility. Other researchers have been able to successfully transport large cargos 
such as beads, vesicles, and cells, but the labeling density of their microtubules is 
significantly less and the kinesins maneuver around individual cargos.[18, 25, 60] To 
sustain motility, the binding density of the analyte could be reduced so that 
kinesin can accommodate for and move around the large cargo in order to 
	   80 
transport these larger constructs. Since reducing the antibody density sacrifices 
the detection limit of the system (Chapter 3.3), I will now explore ways in which 
motility can be sustained while maintaining a high concentration of antibody in 
solution. 
 
Modifying Assay Geometry to Support the Transport of Large Cargos 
The gliding assays reported here were all performed using a 560 amino 
acid long truncated kinesin-1 motor protein. As a result, the motor domains of 
the truncated motor rest very close (~7 nm) to the glass surface that is imaged in 
a gliding assay.[140] A full-length kinesin-1 motor protein is over 900 amino acids 
long and has a length of 58 nm. Using the truncated motor, the long coiled-coiled 
tail domain that makes up 86% of the length of the kinesin motor is not present. 
Since my results (Chapter 4) suggest that sandwich assay motility issues arise 
from steric hindrances, I believe that using a longer or full length kinesin motor 
will promote the transport of larger cargos bound to the microtubule surface will 
by distancing the functionalized microtubule further from the glass surface. 
Because the truncated kinesin are able to support robust motility on a 
microtubule with 5-10% of dimers functionalized, my results suggest that longer 
kinesin constructs could accommodate for a similar density of larger protein 
complexes assuming that longer kinesin molecules are bound to the glass surface 
at a similar density.  
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Modifying MT-Antibody Conjugation Procedure to Support the Transport of 
Large Cargos 
 
Modifying the microtubule-labeling procedure to change the geometry of 
the labeling system may be sufficient in supporting antibody-sandwich assay 
motility without significantly sacrificing the detection capabilities of the system. 
Single molecule studies show that kinesin step linearly along the microtubule 
protofilament.[141] We can take advantage of the gliding assay geometry by 
attaching large cargos to half of the microtubule and leaving the other half of the 
microtubule along the cylindrical axis free for kinesin to bind and step along. The 
existing protocol (Chapter 3.2) functionalizes microtubules as they diffuse freely 
in solution such that the MT labeling is uniform along the MT surface. An 
alternative to this method would be to functionalize MTs while they are bound 
to a kinesin coated surface using an ATP analog, such as adenosine 5’-(β,ϒ-
imido)triphosphate (AMP-PNP), would hold the MT to the surface throughout 
the entire procedure. Using the same assay geometry as the binding capacity 
assays (Figure 3.2), 10 µM AMP-PNP can be added to solution to securely bind 
the microtubules to the kinesin-coated surface. Then, the entire conjugation 
procedure can be done in a glass assay chamber such that the surface of the MT 
that is bound to the kinesin remains unfunctionalized.  
To avoid SMCC crosslinker from binding to kinesin motor, the SMCC-
labeling portion of the protocol can be performed outside of the assay chamber. 
SMCC-coated microtubules can then be added to the assay chamber for antibody 
functionalization. SMCC densely bound to the entire surface of the microtubule 
does not threaten to motility since the crosslinker does not significantly affect 
motility (Figure 3.5). Alternatively, if one wants to perform the entire labeling 
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procedure in an assay chamber, engineered kinesin that limit the number of 
exposed amine binding sites or are cysteine-free can be used to limit crosslinker 
from binding to kinesin. Cysteine-free motors have been engineered and are 
proven to sustain motility in gliding assays.[142]  
Because the kinesin are bound to one side of the microtubule, antibodies 
will not be able to bind along the same protofilament to which the kinesin 
molecules are bound, leaving a lateral surface along the microtubule free from 
antibodies. Assuming that the kinesin coated surface binds to the two nearest 
protofilaments that lie closest to the NKHK560cys kinesin-coated surface and 
that reduced antibodies occupy a volume of approximately 14 nm x 5 nm x 4 nm, 
the reduced sulfhydryl groups on the antibody will be unable to reach the three 
protofilaments lying closest to the kinesin coated surface of the microtubule.[143] 
When three of the thirteen tubulin protofilaments are blocked from binding 
antigen, the binding capacity of the microtubule would be theoretically reduced 
by 23%. Recall that we define R as the concentration of antibody (receptor) in 
solution, L as the concentration of antigen (ligand) in solution, and C, the 
concentration of bound antibody-antigen. The kinetics of our system are  !"!" = !!"!" − !!""!. 
At equilibrium (  !"!" = 0), neglecting the effect of ligand depletion and assuming 
this limit is asymptotically approached for ! ≫ (!!"!!"!#$ + !!"")!!, then !!"#$%$&'$#( = !!"!#$!!"!#$!!!!!"!#$ . 
Therefore, reducing the total concentration of antibodies, Rtotal, in solution 
directly reduces the number of bound antigen, C, which ultimately correlates to 
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the detection limit of the assay. Using realistic antibody densities established in 
this work coupled with a 23% reduction in binding capacity due to the modified 
protocol discussed above, a 10 nL sample containing 5 mm of functionalized MTs 
holding 86 antibodies µm-1 (23% of the maximum 122 antibodies µm-1 established 
previously) would capture five of the six antigen molecules found in a 1 fM 
antigen solution after a 25 minute incubation. This calculation also assumes that 
the antibody-antigen complex has a dissociation constant (KD) ≤ 100 pM and the 
only antibodies in the system are those on the MT surface. Therefore, 
functionalizing microtubules with antibodies while the microtubules are bound 
to a kinesin coated surface would still create functionalized microtubules capable 
of capturing ultralow concentrations of antigen while supporting the transport of 
large cargos.  
 Performing the conjugation procedure in an assay chamber will require 
that assay conditions be re-optimized. Incubation times will need to be adjusted 
to accommodate for the fact that microtubule diffusion is no longer occurring. 
While the SMCC and antibody excesses optimized in this assay will serve as a 
good standard, the conditions should be optimized again to maximize the 
binding capacity of the system. Lastly, since pelleting the microtubules is no 
longer an option given this conjugation protocol, rinse steps should be optimized 
to sufficiently rid the system of excess antibodies and crosslinkers that may 
interfere with the specificity and detection capabilities of the system. If the 
functionalized microtubules are going to be used in the same assay chamber that 
they were functionalized, it is also necessary to ensure that the conjugation 
procedure does not prevent kinesin motility. Leaving kinesin at room 
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temperature for long periods of time (several hours) will negatively impact 
kinesin motility. But once optimized, this modified procedure could produce 
antibody-functionalized microtubules that sustain motility with large, sandwich 
assay constructs as cargos. 
 
Transport Fewer, Larger Cargos to Sustain Motility  
Instead of coating the entire surface of the microtubule with antibody 
sandwich constructs, one alternative is to change the geometry of the system 
such that antibody functionalized microspheres are transported by the 
microtubules. Microspheres can be functionalized with the antibody of interest 
along with a small portion of anti-tubulin antibodies that can bind to the 
microtubule.[12] Binding fewer antibody-functionalized microspheres on the 
microtubule would allow for the microtubule to carry fewer large cargos and 
maintain a high binding antigen binding capacity and, theoretically, not sacrifice 
motility. The size and binding density of the bead can be optimized to realize 
similar (fM) detection limits as the antibody functionalized microtubules. 
 
5.3 Future Work: Kinesin-Driven Immunoassay Platforms 
in Blood Plasma  
As discussed in Chapter 4, existing kinesin-driven platforms that 
autonomously guide microtubules have limited potential to function in blood 
plasma due to the long term (60 minute) effects blood plasma has on the quality 
of gliding assays. Urine looks like a promising body fluid to further characterize 
and determine if urine-based diagnostic tests are a more appropriate platform for 
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kinesin-driven immunoassay technologies. Other samples that have not been 
explored by researchers include cerebrospinal fluid and various types of cell 
lysates. However, because blood derivatives are the existing standard and 
currently offer the broadest application for immunoassays, determining how to 
best incorporate kinesin and microtubules into blood derivatives is imperative in 
advancing the field. As a result, we must assess the known limitations of kinesin-
driven technologies in blood plasma to determine in what direction future 
technologies should proceed.  
 
Separate Sample Collection from Gliding Assays 
Since gliding assay motility in blood plasma deteriorates over time, 
researchers could separate protein collection, or cargo loading, onto the 
microtubule surface from motility. One way this can be accomplished is by 
loading cargos directly onto the microtubule surface while the microtubules are 
held in place on a kinesin-coated surface. Microtubule bundling and aggregation 
is dependent on microtubules interacting with one another. While bound in 
rigor, the microtubules will not have the opportunity to collide with each other 
as the analyte binds to the microtubule surface. However, being bound to a 
surface in rigor does not prevent nonspecific protein-protein interactions from 
occurring, which can cause bundling and floating ends as soon as the 
microtubules become motile. Since the working hypothesis driving the 
conclusions in Chapter 4 is that nonspecific protein-protein interactions drive the 
deterioration of gliding assay motility, several control experiments must be 
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performed to determine if the microtubules and kinesin can recover from being 
exposed to blood plasma. Removing the kinesin-microtubule system completely 
from blood derivatives is another option. 
Microtubules can be completely removed from blood derivatives by using 
a collection mechanism such as an antibody-functionalized microsphere instead 
of functioning the microtubule itself (discussed above) that can be exposed to the 
sample. Microspheres functionalized with antibodies can diffuse freely in body 
fluids without aggregating.[144] After binding the analyte of interest, the 
microspheres can be pelleted out of the sample solution and rinsed through 
centrifugation steps or using a magnet if the beads are paramagnetic. Once the 
beads carrying the analyte are removed from the blood plasma, the beads can 
bind to microtubules through an anti-tubulin antibody or a biotin-streptavidin 
linkage.  
 
Engineer Technologies Accommodating for Motility in Blood Plasma 
By understanding how gliding assay motility changes over time (Chapter 
4.4), engineers can design kinesin-driven technologies to accommodate for these 
characteristics. For example, engineering a kinesin-driven device that runs in 1% 
unfiltered blood plasma for 20 minutes would lead to only a 14% decrease in 
microtubule density with nearly 70% of the microtubules having high quality 
motility, allowing them to be effectively guided via mechanical or electrostatic 
interactions as previously discussed. Reducing the length scales of future 
kinesin-driven technologies such that assays are completed in 20 minutes instead 
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of an hour could be sufficient in sustaining motility in medically relevant 
samples without requiring excessive dilutions or filtration.  
 Removing the importance of high quality motility for microtubule control 
or the need to steer microtubules altogether could accommodate blood plasma 
samples. Instead of the proposed mechanism where a fluorescent signal from 
cargo-carrying MTs would be used for protein detection, researchers could, 
instead, engineer a system where motility itself detects the analyte of interest. 
This could be done by engineering a protein-signaling cascade that releases or 
produces ATP to power the kinesin motors or engineering a microtubule tether 
that releases the microtubule in the presence of an analyte “key” are just two 
examples as to how motility can be used as an analyte signal. Kinesin motor 
molecules can be engineered to have a key mechanism that switches the motor 
from being inhibited to uninhibited and free to traverse along the microtubule. 
Previous work in developing engineered motility switches for the kinesin-
microtubule system is discussed in Chapter 2.1. Taking advantage of advanced 
bioengineering principles can transform the gliding assay geometry into a 
platform for analyte detection in blood plasma with a binary signal (motility and 
no motility). One downfall to these systems is that they would have to be highly 
specific to the analyte, which would make developing a platform that can detect 
multiple analytes laborious and expensive. 
 Alternatively, the assay geometry could be reversed to accommodate for 
the demonstrated robust kinesin motility in blood plasma. By tethering 
microtubules onto a coverglass for kinesin to travel upon, MT aggregation or 
floating ends seen in gliding assays would no longer be relevant. Instead of 
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microtubules serving as microshuttles carrying the cargos, the kinesin motors 
could be engineered to collect and carry specific cargos just as they do naturally 
in biological cells. Individual kinesin motor molecules are not ideal for 
millimeter-scale transport because, depending on the motor, they processively 
move for tens of nanometers to microns. However, if many motors are 
conjugated to a single cargo, the length of their runs increases.[145] Since the 
gliding assay geometry is the assay substrate that engineers have built kinesin-
driven technologies upon, a lot of engineering would need to go into controlling 
the motion of kinesin and the placement of microtubule tracks in a reversed 
assay geometry.  
 
5.4 Future Outlook for Kinesin-Driven Technologies  
As biologists, engineers, and biophysicists continue to study the complex 
intracellular transport system, the potential for incorporating biomolecular 
motors into microfluidic technologies will grow. Inside a biological cell the 
kinesin and microtubule system are highly regulated and support advanced, 
energy efficient transport functions. As we better understand how these systems 
are regulated and controlled, we can incorporate these mechanisms into lab on 
chip devices. As we wait for the secrets of the biology to unravel, engineers have 
the capabilities to manipulate and create advanced biological systems from 
scratch. So long as the field continues with innovation and persistence, the 
kinesin and microtubule system have significant potential for improving POC 
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medical devices over the next several decades as engineering and biology 
progress together.  
	   90 
 
 
 
WORKS CITED 
 
1. Erickson, D. and D.Q. Li, Integrated microfluidic devices. Analytica 
Chimica Acta, 2004. 507(1): p. 11-26. 
2. Lion, N., T.C. Rohner, L. Dayon, I.L. Arnaud, E. Damoc, N. Youhnovski, 
Z.Y. Wu, C. Roussel, J. Josserand, H. Jensen, J.S. Rossier, M. Przybylski, 
and H.H. Girault, Microfluidic systems in proteomics. Electrophoresis, 
2003. 24(21): p. 3533-3562. 
3. Pavlickova, P., E.M. Schneider, and H. Hug, Advances in recombinant 
antibody microarrays. Clinica Chimica Acta, 2004. 343(1-2): p. 17-35. 
4. Sanchez-Carbayo, M., Antibody arrays: Technical considerations and 
clinical applications in cancer. Clinical Chemistry, 2006. 52(9): p. 1651-
1659. 
5. Sanders, G.H.W. and A. Manz, Chip-based microsystems for genomic and 
proteomic analysis. Trac-Trends in Analytical Chemistry, 2000. 19(6): p. 
364-378. 
6. Stoll, D., M.F. Templin, J. Bachmann, and T.O. Joos, Protein microarrays: 
Applications and future challenges. Current Opinion in Drug Discovery & 
Development, 2005. 8(2): p. 239-252. 
7. Wilson, D.S. and S. Nock, Functional protein microarrays. Current 
Opinion in Chemical Biology, 2002. 6(1): p. 81-85. 
8. Schmechel, D., R.L. Gorny, J.P. Simpson, T. Reponen, S.A. Grinshpun, and 
D.M. Lewis, Limitations of monoclonal antibodies for monitoring of 
fungal aerosols using Penicillium brevicompactum as a model fangus. 
Journal of Immunological Methods, 2003. 283(1-2): p. 235-245. 
9. Zhou, F., M. Wang, L. Yuan, Z. Cheng, Z. Wu, and H. Chen, Sensitive 
sandwich ELISA based on a gold nanoparticle layer for cancer detection. 
Analyst, 2012. 137(8): p. 1779-1784. 
	   91 
10. Zhu, L. and E.V. Anslyn, Signal amplification by allosteric catalysis. 
Angewandte Chemie-International Edition, 2006. 45(8): p. 1190-1196. 
11. Barletta, J.M., D.C. Edelman, and N.T. Constantine, Lowering the 
detection limits of HIV-1 viral load using real-time Immuno-PCR for HIV-
1 p24 antigen. American Journal of Clinical Pathology, 2004. 122(1): p. 20-
27. 
12. Chan, C.P.-y., Y.-c. Cheung, R. Renneberg, and M. Seydack, New trends in 
immunoassays, in Biosensing for the 21st Century, R.L.F. Renneberg, Editor 
2008. p. 123-154. 
13. Schweitzer, B., S. Roberts, B. Grimwade, W.P. Shao, M.J. Wang, Q. Fu, 
Q.P. Shu, I. Laroche, Z.M. Zhou, V.T. Tchernev, J. Christiansen, M. 
Velleca, and S.F. Kingsmore, Multiplexed protein profiling on microarrays 
by rolling-circle amplification. Nature Biotechnology, 2002. 20(4): p. 359-
365. 
14. Bachand, G.D., H. Hess, B. Ratna, P. Satir, and V. Vogel, "Smart dust'' 
biosensors powered by biomolecular motors. Lab on a Chip, 2009. 9(12): p. 
1661-1666. 
15. van den Heuvel, M.G.L. and C. Dekker, Motor proteins at work for 
nanotechnology. Science, 2007. 317(5836): p. 333-336. 
16. Hess, H., G.D. Bachand, and V. Vogel, Powering nanodevices with 
biomolecular motors. Chemistry-a European Journal, 2004. 10(9): p. 2110-
2116. 
17. Hess, H. and V. Vogel, Molecular shuttles based on motor proteins: active 
transport in synthetic environments. Journal of biotechnology, 2001. 82(1): 
p. 67-85. 
18. Vogel, V. and H. Hess, NanoShuttles: Harnessing motor proteins to transport 
cargo in synthetic environments, in Controlled Nanoscale Motion, H. Linke and 
A. Mansson, Editors. 2007. p. 367-383. 
19. Agarwal, A. and H. Hess, Biomolecular motors at the intersection of 
nanotechnology and polymer science. Progress in Polymer Science, 2010. 
35(1-2): p. 252-277. 
	   92 
20. Bruce Alberts, A.J., Julian Lewis, Martin Raff, Keith Roberts, and Peter 
Walter, Molecular Biology of the Cell. 5th ed2002, New York: Garland 
Science. 
21. Ronald Vale, T.F., Daniel Pierce, Laura Romberg, Yoshie Harada & Toshio 
Yanagida, Direct observation of single kinesin molecules moving along 
microtubules. Letters to Nature, 1996. 380(4 April): p. 451-453. 
22. Rosi, N.L. and C.A. Mirkin, Nanostructures in biodiagnostics. Chemical 
Reviews, 2005. 105(4): p. 1547-1562. 
23. Fischer, T., A. Agarwal, and H. Hess, A smart dust biosensor powered by 
kinesin motors. Nature Nanotechnology, 2009. 4(3): p. 162-166. 
24. Goel, A. and V. Vogel, Harnessing biological motors to engineer systems 
for nanoscale transport and assembly. Nature Nanotechnology, 2008. 3(8): 
p. 465-475. 
25. Korten, T., A. MÂnsson, and S. Diez, Towards the application of 
cytoskeletal motor proteins in molecular detection and diagnostic devices. 
Current Opinion in Biotechnology, 2010. 21(4): p. 477-488. 
26. Bohm, K.J., J. Beeg, G.M. zu Horste, R. Stracke, and E. Unger, Kinesin-
driven sorting machine on large-scale microtubule arrays. Ieee 
Transactions on Advanced Packaging, 2005. 28(4): p. 571-576. 
27. Hancock, W.O. and J. Howard, Processivity of the motor protein kinesin 
requires two heads. Journal of Cell Biology, 1998. 140(6): p. 1395-1405. 
28. Hancock, W.O. and J. Howard, Kinesin's processivity results from 
mechanical and chemical coordination between the ATP hydrolysis cycles 
of the two motor domains. Proceedings of the National Academy of 
Sciences of the United States of America, 1999. 96(23): p. 13147-13152. 
29. Jia, L.L., S.G. Moorjani, T.N. Jackson, and W.O. Hancock, Microscale 
transport and sorting by kinesin molecular motors. Biomedical 
Microdevices, 2004. 6(1): p. 67-74. 
30. Uppalapati, M., Y.-M. Huang, T.N. Jackson, and W.O. Hancock, 
Enhancing the stability of kinesin motors for microscale transport 
applications. Lab on a Chip, 2008. 8(2): p. 358-361. 
	   93 
31. Uppalapati, M., Y.-M. Huang, S. Shastry, T.N. Jackson, and W.O. Hancock, 
Microtubule Motors in Microfluidics. Methods in Bioengineering: 
Biomicrofabrication and Biomicrofluidics, ed. J.D. Zahn2010. 311-337. 
32. Malcos, J.L. and W.O. Hancock, Engineering tubulin: microtubule 
functionalization approaches for nanoscale device applications. Applied 
Microbiology and Biotechnology, 2011. 90(1): p. 1-10. 
33. Bachand, G.D., S.B. Rivera, A. Carroll-Portillo, H. Hess, and M. Bachand, 
Active capture and transport of virus particles using a biomolecular 
motor-driven, nanoscale antibody sandwich assay. Small, 2006. 2(3): p. 
381-385. 
34. Taira, S., Y.-Z. Du, Y. Hiratsuka, K. Konishi, T. Kubo, T.Q.P. Uyeda, N. 
Yumoto, and M. Kodaka, Selective detection and transport of fully 
matched DNA by DNA-loaded microtubule and kinesin motor protein. 
Biotechnology and Bioengineering, 2006. 95(3): p. 533-538. 
35. Diez, S., C. Reuther, C. Dinu, R. Seidel, M. Mertig, W. Pompe, and J. 
Howard, Stretching and transporting DNA molecules using motor 
proteins. Nano Letters, 2003. 3(9): p. 1251-1254. 
36. Dinu, C.Z., J. Opitz, W. Pompe, J. Howard, M. Mertig, and S. Diez, Parallel 
manipulation of bifunctional DNA molecules on structured surfaces using 
kinesin-driven microtubules. Small, 2006. 2(8-9): p. 1090-1098. 
37. Yokokawa, R., J. Miwa, M.C. Tarhan, H. Fujita, and M. Kasahara, DNA 
molecule manipulation by motor proteins for analysis at the single-
molecule level. Analytical and Bioanalytical Chemistry, 2008. 391(8): p. 
2735-2743. 
38. Agarwal, A., P. Katira, and H. Hess, Millisecond Curing Time of a 
Molecular Adhesive Causes Velocity-Dependent Cargo-Loading of 
Molecular Shuttles. Nano Letters, 2009. 9(3): p. 1170-1175. 
39. Boal, A.K., G.D. Bachand, S.B. Rivera, and B.C. Bunker, Interactions 
between cargo-carrying biomolecular shuttles. Nanotechnology, 2006. 
17(2): p. 349-354. 
40. Bachand, G.D., S.B. Rivera, A.K. Boal, J. Gaudioso, J. Liu, and B.C. Bunker, 
Assembly and transport of nanocrystal CdSe quantum dot 
	   94 
nanocomposites using microtubules and kinesin motor proteins. Nano 
Letters, 2004. 4(5): p. 817-821. 
41. Ramachandran, S., K.H. Ernst, G.D. Bachand, V. Vogel, and H. Hess, 
Selective loading of kinesin-powered molecular shuttles with protein 
cargo and its application to biosensing. Small, 2006. 2(3): p. 330-334. 
42. Soto, C.M., B.D. Martin, K.E. Sapsford, A.S. Blum, and B.R. Ratna, Toward 
single molecule detection of staphylococcal enterotoxin B: Mobile 
sandwich immunoassay on gliding microtubules. Analytical Chemistry, 
2008. 80(14): p. 5433-5440. 
43. Liu, H., E.D. Spoerke, M. Bachand, S.J. Koch, B.C. Bunker, and G.D. 
Bachand, Biomolecular Motor-Powered Self-Assembly of Dissipative 
Nanocomposite Rings. Advanced Materials, 2008. 20(23): p. 4476-4481. 
44. Hess, H., J. Clemmens, C. Brunner, R. Doot, S. Luna, K.H. Ernst, and V. 
Vogel, Molecular self-assembly of "nanowires" and "nanospools" using 
active transport. Nano Letters, 2005. 5(4): p. 629-633. 
45. Rios, L. and G.D. Bachand, Multiplex transport and detection of cytokines 
using kinesin-driven molecular shuttles. Lab on a Chip, 2009. 9(7): p. 1005-
1010. 
46. Carroll-Portillo, A., M. Bachand, and G.D. Bachand, Directed Attachment 
of Antibodies to Kinesin-Powered Molecular Shuttles. Biotechnology and 
Bioengineering, 2009. 104(6): p. 1182-1188. 
47. Liepelt, S. and R. Lipowsky, Kinesin's network of chemomechanical motor 
cycles. Physical Review Letters, 2007. 98(25): p. 258102-258102. 
48. Romberg, L. and R.D. Vale, CHEMOMECHANICAL CYCLE OF KINESIN 
DIFFERS FROM THAT OF MYOSIN. Nature, 1993. 361(6408): p. 168-170. 
49. Adio, S., J. Reth, F. Bathe, and G. Woehlke, Review: regulation 
mechanisms of Kinesin-1. Journal of Muscle Research and Cell Motility, 
2006. 27(2): p. 153-160. 
50. Hirokawa, N., R. Nitta, and Y. Okada, The mechanisms of kinesin motor 
motility: lessons from the monomeric motor KIF1A. Nature Reviews 
Molecular Cell Biology, 2009. 10(12): p. 877-884. 
	   95 
51. Reilein, A.R., S.L. Rogers, M.C. Tuma, and V.I. Gelfand, Regulation of 
molecular motor proteins, in International Review of Cytology - a Survey of Cell 
Biology, Vol 204, K.W. Jeon, Editor 2001. p. 179-238. 
52. Verhey, K.J. and T.A. Rapoport, Kinesin carries the signal. Trends in 
Biochemical Sciences, 2001. 26(9): p. 545-550. 
53. Brunner, C., C. Wahnes, and V. Vogel, Cargo pick-up from engineered 
loading stations by kinesin driven molecular shuttles. Lab on a Chip, 2007. 
7(10): p. 1263-1271. 
54. Hiyama, S., T. Inoue, T. Shima, Y. Moritani, T. Suda, and K. Sutoh, 
Autonomous Loading, Transport, and Unloading of Specified Cargoes by 
Using DNA Hybridization and Biological Motor-Based Motility. Small, 
2008. 4(4): p. 410-415. 
55. Schmidt C and Vogel V, Molecular shuttles powered by motor proteins: 
loading and unloading stations for nanocargo integrated into one device. 
(1473-0197 (Print)). 
56. Hiyama, S., R. Gojo, T. Shima, S. Takeuchi, and K. Sutoh, Biomolecular-
Motor-Based Nano- or Microscale Particle Translocations on DNA 
Microarrays. Nano Letters, 2009. 9(6): p. 2407-2413. 
57. Hiyama, S., T. Inoue, T. Shima, Y. Moritani, T. Suda, and K. Sutoh, 
Autonomous molecular sorting by DNA labeled microtubules. 
Biophysical Journal, 2007: p. 331A-331A. 
58. Hiyama, S., Y. Moritani, R. Gojo, S. Takeuchi, and K. Sutoh, Biomolecular-
motor-based autonomous delivery of lipid vesicles as nano- or microscale 
reactors on a chip. Lab on a Chip, 2010. 10(20): p. 2741-2748. 
59. Hiyama, S., Y. Moritani, S. Takeuchi, and K. Sutoh, Selective Capture and 
Transport of Lipid Vesicles by Using DNAs and Biomolecular Motors. Fourth 
International Conference on Quantum, Nano and Micro Technologies: 
Icqnm 2010, Proceedings, ed. V. Ovchinnikov2010. 23-26. 
60. Hiyama, S., S. Takeuchi, R. Gojo, T. Shima, K. Sutoh, and Ieee, Biomolecular 
motor-based cargo transporters with loading/unloading mechanisms on a micro-
patterned DNA array, in Mems 2008: 21st Ieee International Conference on 
Micro Electro Mechanical Systems, Technical Digest2008. p. 144-147. 
	   96 
61. Ionov, L., M. Stamm, and S. Diez, Reversible Switching of Microtubule 
Motility Using Thermoresponsive Polymer Surfaces. Nano Letters, 2006. 
6(9): p. 1982-1987. 
62. Rahim, M.K.A., T. Kamei, and N. Tamaoki, Dynamic photo-control of 
kinesin on a photoisomerizable monolayer - hydrolysis rate of ATP and 
motility of microtubules depending on the terminal group. Organic & 
Biomolecular Chemistry, 2012. 10(16): p. 3321-3331. 
63. Hess, H., J. Clemmens, D. Qin, J. Howard, and V. Vogel, Light-controlled 
molecular shuttles made from motor proteins carrying cargo on 
engineered surfaces. Nano Letters, 2001. 1(5): p. 235-239. 
64. Korten, T., W. Birnbaum, D. Kuckling, and S. Diez, Selective Control of 
Gliding Microtubule Populations. Nano Letters, 2012. 12(1): p. 348-353. 
65. Fan, R., O. Vermesh, A. Srivastava, B.K.H. Yen, L. Qin, H. Ahmad, G.A. 
Kwong, C.-C. Liu, J. Gould, L. Hood, and J.R. Heath, Integrated barcode 
chips for rapid, multiplexed analysis of proteins in microliter quantities of 
blood. Nature Biotechnology, 2008. 26(12): p. 1373-1378. 
66. Bohm, K.J., R. Stracke, M. Baum, M. Zieren, and E. Unger, Effect of 
temperature on kinesin-driven microtubule gliding and kinesin ATPase 
activity. Febs Letters, 2000. 466(1): p. 59-62. 
67. Bohm, K.J., R. Stracke, and E. Unger, Speeding up kinesin-driven 
microtubule gliding in vitro by variation of cofactor composition and 
physicochemical parameters. Cell Biology International, 2000. 24(6): p. 
335-341. 
68. Greene, A.C., A.M. Trent, and G.D. Bachand, Controlling kinesin motor 
proteins in nanoengineered systems through a metal-binding on/off 
switch. Biotechnology and Bioengineering, 2008. 101(3): p. 478-486. 
69. Grant, B.J., R.A. Cross, and J.A. McCammon, Electrostatically Biased 
Binding of Kinesin to Microtubules. Biophysical Journal, 2011. 100(3): p. 
121-121. 
70. Grant, B.J., J.A. McCammon, L.S.D. Caves, and R.A. Cross, Multivariate 
analysis of conserved sequence-structure relationships in kinesins: 
Coupling of the active site and a tubulin-binding sub-domain. Journal of 
Molecular Biology, 2007. 368(5): p. 1231-1248. 
	   97 
71. Lin, C.-T., M.-T. Kao, E. Meyhofer, and K. Kurabayashi, Surface landing of 
microtubule nanotracks influenced by lithographically patterned 
channels. Applied Physics Letters, 2009. 95(10). 
72. Lin, C.-T., E. Meyhofer, and K. Kurabayashi, Predicting the stochastic 
guiding of kinesin-driven microtubules in microfabricated tracks: A 
statistical-mechanics-based modeling approach. Physical Review E, 2010. 
81(1). 
73. Gittes, F., B. Mickey, J. Nettleton, and J. Howard, FLEXURAL RIGIDITY 
OF MICROTUBULES AND ACTIN-FILAMENTS MEASURED FROM 
THERMAL FLUCTUATIONS IN SHAPE. Journal of Cell Biology, 1993. 
120(4): p. 923-934. 
74. Clemmens, J., H. Hess, R. Lipscomb, Y. Hanein, K.F. Bohringer, C.M. 
Matzke, G.D. Bachand, B.C. Bunker, and V. Vogel, Mechanisms of 
microtubule guiding on microfabricated kinesin-coated surfaces: Chemical 
and topographic surface patterns. Langmuir, 2003. 19(26): p. 10967-10974. 
75. Moorjani, S.G., L. Jia, T.N. Jackson, and W.O. Hancock, Lithographically 
patterned channels spatially segregate kinesin motor activity and 
effectively guide microtubule movements. Nano Letters, 2003. 3(5): p. 633-
637. 
76. Huang, Y.M., M. Uppalapati, W.O. Hancock, and T.N. Jackson, 
Microfabricated capped channels for biomolecular motor-based transport. 
Ieee Transactions on Advanced Packaging, 2005. 28(4): p. 564-570. 
77. Huang, Y.-M., M. Uppalapati, W.O. Hancock, and T.N. Jackson, 
Microtubule transport, concentration and alignment in enclosed 
microfluidic channels. Biomedical Microdevices, 2007. 9(2): p. 175-184. 
78. Verma, V., W.O. Hancock, and J.M. Catchmark, Nanoscale patterning of 
kinesin motor proteins and its role in guiding microtubule motility. 
Biomedical Microdevices, 2009. 11(2): p. 313-322. 
79. Lin, C.T., M.T. Kao, K. Kurabayashi, and E. Meyhofer, Efficient designs for 
powering microscale devices with nanoscale biomolecular motors. Small, 
2006. 2(2): p. 281-287. 
	   98 
80. Lin, C.-T., M.-T. Kao, K. Kurabayashi, and E. Meyhofer, Self-contained 
biomolecular motor-driven protein sorting and concentrating in an 
ultrasensitive microfluidic chip. Nano Letters, 2008. 8(4): p. 1041-1046. 
81. Doot, R.K., H. Hess, and V. Vogel, Engineered networks of oriented 
microtubule filaments for directed cargo transport. Soft Matter, 2007. 3(3): 
p. 349-356. 
82. Clemmens, J., H. Hess, R. Doot, C.M. Matzke, G.D. Bachand, and V. Vogel, 
Motor-protein "roundabouts": Microtubules moving on kinesin-coated 
tracks through engineered networks. Lab on a Chip, 2004. 4(2): p. 83-86. 
83. Bachand, M., A.M. Trent, B.C. Bunker, and G.D. Bachand, Physical factors 
affecting kinesin-based transport of synthetic nanoparticle cargo. Journal 
of Nanoscience and Nanotechnology, 2005. 5(5): p. 718-722. 
84. Korten, T. and S. Diez, Setting up roadblocks for kinesin-1: mechanism for 
the selective speed control of cargo carrying microtubules. Lab on a Chip, 
2008. 8(9): p. 1441-1447. 
85. Leduc, C., K. Padberg-Gehle, V. Varga, D. Helbing, S. Diez, and J. 
Howard, Molecular crowding creates traffic jams of kinesin motors on 
microtubules. Proceedings of the National Academy of Sciences of the 
United States of America, 2012. 109(16): p. 6100-6105. 
86. Kis, A., S. Kasas, B. BabiÄ‡, A.J. Kulik, W. Benoît, G.A.D. Briggs, C. 
Schönenberger, S. Catsicas, and L. Forró, Nanomechanics of Microtubules. 
Physical Review Letters, 2002. 89(Copyright (C) 2010 The American 
Physical Society): p. 248101. 
87. Sugita, S., T. Murase, N. Sakamoto, T. Ohashi, and M. Sato, Size sorting of 
kinesin-driven microtubules with topographical grooves on a chip. Lab on 
a Chip, 2010. 10(6): p. 755-761. 
88. Stracke, R., K.J. Bohm, L. Wollweber, J.A. Tuszynski, and E. Unger, 
Analysis of the migration behaviour of single microtubules in electric 
fields. Biochemical and Biophysical Research Communications, 2002. 
293(1): p. 602-609. 
89. van den Heuvel, M.G.L., M.P. De Graaff, and C. Dekker, Molecular 
sorting by electrical steering of microtubules in kinesin-coated channels. 
Science, 2006. 312(5775): p. 910-914. 
	   99 
90. Kim, T., M.T. Kao, E.F. Hasselbrink, and E. Meyhofer, Active alignment of 
microtubules with electric fields. Nano Letters, 2007. 7(1): p. 211-217. 
91. Uppalapati, M., Y.-M. Huang, T.N. Jackson, and W.O. Hancock, 
Microtubule alignment and manipulation using AC electrokinetics. Small, 
2008. 4(9): p. 1371-1381. 
92. Hutchins, B.M., W.O. Hancock, and M.E. Williams, Magnet assisted 
fabrication of microtubule arrays. Physical Chemistry Chemical Physics, 
2006. 8(30): p. 3507-3509. 
93. Giljohann, D.A. and C.A. Mirkin, Drivers of biodiagnostic development. 
Nature, 2009. 462(7272): p. 461-464. 
94. Yager, P., T. Edwards, E. Fu, K. Helton, K. Nelson, M.R. Tam, and B.H. 
Weigl, Microfluidic diagnostic technologies for global public health. 
Nature, 2006. 442(7101): p. 412-418. 
95. Gervais, L. and E. Delamarche, Toward one-step point-of-care 
immunodiagnostics using capillary-driven microfluidics and PDMS 
substrates. Lab on a Chip, 2009. 9(23): p. 3330-3337. 
96. Goodchild, S., T. Love, N. Hopkins, and C. Mayers, Engineering antibodies 
for biosensor technologies, in Advances in Applied Microbiology, Vol 58, 
A.I.B.J.W.G.G.M.S.S. Laskin, Editor 2006. p. 185-226. 
97. Altshuler, E.P., D.V. Serebryanaya, and A.G. Katrukha, Generation of 
recombinant antibodies and means for increasing their affinity. 
Biochemistry-Moscow, 2010. 75(13): p. 1584-1605. 
98. Boder, E.T., K.S. Midelfort, and K.D. Wittrup, Directed evolution of 
antibody fragments with monovalent femtomolar antigen-binding 
affinity. Proceedings of teh National Academy of Sciences of the United 
States of America, 2000. 97(20): p. 10701-10705. 
99. Bradbury, A.R.M., S. Sidhu, S. Duebel, and J. McCafferty, Beyond natural 
antibodies: the power of in vitro display technologies. Nature 
Biotechnology, 2011. 29(3): p. 245-254. 
100. Chmura, A.J., M.S. Orton, and C.F. Meares, Antibodies with infinite 
affinity. Proceedings of the National Academy of Sciences of the United 
States of America, 2001. 98(15): p. 8480-8484. 
	   100 
101. Colby, D.W., B.A. Kellogg, C.P. Graff, Y.A. Yeung, J.S. Swers, and K.D. 
Wittrup, Engineering antibody affinity by yeast surface display. Protein 
Engineering, 2004. 388: p. 348-358. 
102. Kobayashi, N., Y. Kato, H. Oyama, and J. Goto, Antibody engineering-
based approach for hapten immunometric assays with high sensitivity. 
Yakugaku Zasshi-Journal of the Pharmaceutical Society of Japan, 2007. 
127(1): p. 55-69. 
103. Lippow, S.M., K.D. Wittrup, and B. Tidor, Computational design of 
antibody-affinity improvement beyond in vivo maturation. Nature 
Biotechnology, 2007. 25(10): p. 1171-1176. 
104. Starwalt, S.E., E.L. Masteller, J.A. Bluestone, and D.M. Kranz, Directed 
evolution of a single-chain class II MHC product by yeast display. Protein 
Engineering, 2003. 16(2): p. 147-156. 
105. van den Beucken, T., H. Pieters, M. Steukers, M. van der Vaart, R.C. 
Ladner, H.R. Hoogenboom, and S.E. Hufton, Affinity maturation of Fab 
antibody fragments by fluorescent-activated cell sorting of yeast-
displayed libraries. Febs Letters, 2003. 546(2-3): p. 288-294. 
106. Weaver-Feldhaus, J.M., K.D. Miller, M.J. Feldhaus, and R.W. Siegel, 
Directed evolution for the development of conformation-specific affinity 
reagents using yeast display. Protein Engineering Design & Selection, 
2005. 18(11): p. 527-536. 
107. Quake, S., Microfluidics: Fluid physics at the nanoliter scale. Reviews of 
Modern Physics, 2005. 77: p. 977-1026. 
108. Song, S.Y., Y.D. Han, S.Y. Hong, K. Kim, S.S. Yang, B.-H. Min, and H.C. 
Yoon, Chip-based cartilage oligomeric matrix protein detection in serum 
and synovial fluid for osteoarthritis diagnosis. Analytical Biochemistry, 
2012. 420(2): p. 139-146. 
109. Matsunaga, T., Y. Maeda, T. Yoshino, H. Takeyama, M. Takahashi, H. 
Ginya, J. Aasahina, and H. Tajima, Fully automated immunoassay for 
detection of prostate-specific antigen using nano-magnetic beads and 
micro-poly styrene bead composites, 'Beads on Beads'. Analytica Chimica 
Acta, 2007. 597(2): p. 331-339. 
	   101 
110. Scientific, T., Automated Magnetic Separations for Proteomics, P.P.B. 
Products, Editor 2012, Thermo Fisher Scientific Inc.: Rockford. 
111. Healthcare, G. Biacore. 2012  [cited 2011 September 14]. 
112. RDTinfo: Current Information on Rapid Diagnostic Tests. 2008  [cited 2011 
September 14]; http://www.rapid-diagnostics.org/technologies.htm%5D. 
113. Schutzer, S.E., T. Liu, B.H. Natelson, T.E. Angel, A.A. Schepmoes, S.O. 
Purvine, K.K. Hixson, M.S. Lipton, D.G. Camp, II, P.K. Coyle, R.D. Smith, 
and J. Bergquist, Establishing the Proteome of Normal Human 
Cerebrospinal Fluid. PLoS ONE, 2010. 5(6): p. e10980. 
114. Anderson, N. and N. Anderson, The human plasma proteome: history, 
character, and diagnostic prospects. Mol Cell Proteomics, 2002. 1(11): p. 
845-67. 
115. Manuel, Y., J.P. Revillard, and H. Betuel, Proteins in Normal and Pathological 
Urine1970, Baltimore and Manchester: University Park Press. 
116. Yoshizawa, J.M., C.A. Schafer, J.J. Schafer, J.J. Farrell, B.J. Paster, and D.T. 
Wong, Salivary biomarkers: toward future clinical and diagnostic utilities. 
Clin Microbiol Rev, 2013. 26(4): p. 781-91. 
117. Rasia, M. and A. Bollini, Red blood cell shape as a function of 
medium‚Äôs ionic strength and pH. Biochimica et Biophysica Acta (BBA) 
- Biomembranes, 1998. 1372(2): p. 198-204. 
118. Korten, S., N. Albet-Torres, F. Paderi, L.t. Siethoff, S. Diez, T. Korten, G.t. 
Kronnie, and A. Mansson, Sample solution constraints on motor-driven 
diagnostic nanodevices. Lab Chip, 2013. 13(5): p. 866-76. 
119. Lee, W.G., Y.-G. Kim, B.G. Chung, U. Demirci, and A. Khademhosseini, 
Nano/Microfluidics for diagnosis of infectious diseases in developing 
countries. Advanced Drug Delivery Reviews, 2010. 62(4-5): p. 449-457. 
120. Rosen, Y. and P. Gurman, MEMS and Microfluidics for Diagnostics 
Devices. Current Pharmaceutical Biotechnology, 2010. 11(4): p. 366-375. 
121. Barradas, R.G., S. Fletcher, and J.D. Porter, The hydrolysis of maleimide in 
alkaline solution. Canadian Journal of Chemistry, 1976. 54(9): p. 1400-1404. 
122. Scientific, T., Instructions 2-Mercaptoethylamine HCl, P. Biotechnology, 
Editor: Rockford. 
	   102 
123. Hermanson, G.T., Bioconjugate Techniques. Second ed2008, London: 
Elsevier. 
124. Curtis, R.A. and L. Lue, A molecular approach to bioseparations: Protein-
protein and protein-salt interactions. Chemical Engineering Science, 2006. 
61(3): p. 907-923. 
125. Abul Abbas, A.L., Shiv Pillai, Cellular and Molecular Immunology. 7th 
ed2012, Philadelphia: Elsevier Inc. 
126. Castoldi, M. and A.V. Popova, Purification of brain tubulin through two 
cycles of polymerization-depolymerization in a high-molarity buffer. 
Protein Expression and Purification, 2003. 32(1): p. 83-88. 
127. Lakamper, S. and E. Meyhofer, The E-hook of tubulin interacts with 
kinesin's head to increase processivity and speed. Biophysical Journal, 
2005. 89(5): p. 3223-3234. 
128. Stirling, P.C., V.F. Lundin, and M.R. Leroux, Getting a grip on non-native 
proteins. Embo Reports, 2003. 4(6): p. 565-570. 
129. Phizicky, E.M. and S. Fields, PROTEIN-PROTEIN INTERACTIONS - 
METHODS FOR DETECTION AND ANALYSIS. Microbiological 
Reviews, 1995. 59(1): p. 94-123. 
130. Sreebny, L.M., STUDIES OF SALIVARY GLAND PROTEASES*. Annals of 
the New York Academy of Sciences, 1960. 85(1): p. 182-188. 
131. Yu, Z., G. Kastenm√ºller, Y. He, P. Belcredi, G. M√∂ller, C. Prehn, J. 
Mendes, S. Wahl, W. Roemisch-Margl, U. Ceglarek, A. Polonikov, N. 
Dahmen, H. Prokisch, L. Xie, Y. Li, H.E. Wichmann, A. Peters, F. 
Kronenberg, K. Suhre, J. Adamski, T. Illig, and R. Wang-Sattler, 
Differences between Human Plasma and Serum Metabolite Profiles. PLoS 
ONE, 2011. 6(7): p. e21230. 
132. Ponsel, D., J. Neugebauer, K. Ladetzki-Baehs, and K. Tissot, High Affinity, 
Developability and Functional Size: The Holy Grail of Combinatorial 
Antibody Library Generation. Molecules, 2011. 16(5): p. 3675-3700. 
133. Mock Dm and Malik Mi, Distribution of biotin in human plasma: most of 
the biotin is not bound to protein. (0002-9165 (Print)). 
	   103 
134. Kawamura, R., A. Kakugo, Y. Osada, and J.P. Gong, Microtubule bundle 
formation driven by ATP: the effect of concentrations of kinesin, 
streptavidin and microtubules. Nanotechnology, 2010. 21(14). 
135. Scott, C.W., A.B. Klika, M.M.S. Lo, T.E. Norris, and C.B. Caputo, Tau 
protein induces bundling of microtubules in vitro: Comparison of 
different tau isoforms and a tau protein fragment. Journal of Neuroscience 
Research, 1992. 33(1): p. 19-29. 
136. Sanchez, T. and Z. Dogic, Engineering Oscillating Microtubule Bundles, in 
Cilia, Pt A, W.F. Marshall, Editor 2013. p. 205-224. 
137. Liu, Y., Y. Guo, J.M. Valles, and J.X. Tang, Microtubule bundling and 
nested buckling drive stripe formation in polymerizing tubulin solutions. 
Proceedings of the National Academy of Sciences, 2006. 103(28): p. 10654-
10659. 
138. Kurz Jc and Williams Rc, Jr., Microtubule-associated proteins and the 
flexibility of microtubules. (0006-2960 (Print)). 
139. Thavasu, P., S. Longhurst, S. Joel, M. Slevin, and F. Balkwill, Measuring 
cytokine levels in blood. Importance of anticoagulants, processing, and 
storage conditions. Journal of Immunological Methods, 1992. 153(1-2): p. 
115-24. 
140. Kerssemakers, J., J. Howard, H. Hess, and S. Diez, The distance that 
kinesin-1 holds its cargo from the microtubule surface measured by 
fluorescence interference contrast microscopy. Proceedings of the National 
Academy of Sciences, 2006. 103(43): p. 15812-15817. 
141. Ray, S., E. Meyh√∂fer, R.A. Milligan, and J. Howard, Kinesin follows the 
microtubule's protofilament axis. The Journal of Cell Biology, 1993. 121(5): 
p. 1083-1093. 
142. Iwatani, S., A.H. Iwane, H. Higuchi, Y. Ishii, and T. Yanagida, Mechanical 
and Chemical Properties of Cysteine-Modified Kinesin Molecules. 
Biochemistry, 1999. 38(32): p. 10318-10323. 
143. Foley, J.O., K.E. Nelson, A. Mashadi-Hossein, B.A. Finlayson, and P. 
Yager, Concentration Gradient Immunoassay. 2. Computational Modeling 
for Analysis and Optimization. Analytical Chemistry, 2007. 79(10): p. 
3549-3553. 
	   104 
144. Morozov, V.N. and T.Y. Morozova, Active bead-linked immunoassay on 
protein microarrays. Analytica Chimica Acta, 2006. 564(1): p. 40-52. 
145. Diehl, M.R., K. Zhang, H.J. Lee, and D.A. Tirrell, Engineering 
Cooperativity in Biomotor-Protein Assemblies. Science, 2006. 311(5766): p. 
1468-1471. 
 
